content: <HTML>
  <HEAD>
       <TITLE></TITLE>
  </HEAD>
  <BODY STYLE="font: 10pt Times New Roman, Times, Serif">
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>As filed with the Securities and Exchange Commission
  on September 7, 2022</B></P>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><B>Registration No.</B>&nbsp;<B>333-</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
  
  
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE
  COMMISSION</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549
  </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM S-8</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>REGISTRATION STATEMENT
  UNDER THE SECURITIES ACT OF 1933 </B>&nbsp;</P>
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>AIkido Pharma, Inc.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact Name of Registrant
  as Specified in its Charter)</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_001.jpg" ALT=""></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: Black 1.5pt solid; width: 49%; text-align: center"><B>Delaware</B></TD>
      <TD STYLE="text-align: center; width: 2%">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1.5pt solid; width: 49%; text-align: center"><B>52-0849320</B></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: center">(State or Other Jurisdiction of<BR>
   Incorporation or Organization)</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD STYLE="text-align: center">(I.R.S. Employer<BR>
   Identification No.)</TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>One Rockefeller Plaza,
  11<SUP>th</SUP>&nbsp;Floor </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>New York, NY 10020</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of Principal Executive
  Offices) (Zip Code)</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AIkido Pharma, Inc. 2014 Equity Incentive Plan</B></P>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Full Title of the Plan)</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Anthony Hayes</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Chief Executive Officer</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>One Rockefeller Plaza,
  11<SUP>th</SUP>&nbsp;Floor </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>New York, NY 10020</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Name and Address of Agent
  for Service)</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(703) 992-9325</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Telephone Number, including
  area code, of agent for service)</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Copies to:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Robert F. Charron, Esq.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Sarah Williams, Esq.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Ellenoff Grossman &amp;
  Schole LLP</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>1345 Avenue of Americas,
  11th Floor</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>New York, New York 10105</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(212) 370-1300</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Fax: (212) 370-7889</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><B>Indicate by check mark whether the Registrant
  is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company.
  See definitions of </B>&ldquo;<B>large accelerated filer,</B>&rdquo; &ldquo;<B>accelerated filer,</B>&rdquo; &ldquo;<B>smaller reporting
  company</B>&rdquo; <B>and </B>&ldquo;<B>emerging growth company</B>&rdquo; <B>in Rule 12b-2 of the Exchange Act.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 60%">Large accelerated filer <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD>
      <TD STYLE="width: 40%">Accelerated filer <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>Non-accelerated filer <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9745;</FONT></TD>
      <TD>Smaller reporting company <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9745;</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>Emerging growth company <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>
  
  <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt">If an emerging growth company, indicate by check
  mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
  standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></P>
  
  <!-- Field: Page; Sequence: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B>Explanatory Note</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This Registration Statement on
  Form S-8 of AIkido Pharma, Inc. (&ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our&rdquo; or the &ldquo;Company&rdquo;) has been prepared
  in accordance with the requirements of Form S-8 under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), to (i)
  register 288,108 shares of our common stock, par value $0.0001 per share, to be issued pursuant to the AIkido Pharma, Inc. 2014 Equity
  Incentive Plan, as described in more detail herein, including registering for resale pursuant to a reoffer prospectus certain securities
  to be issued to our officers and directors upon exercise of outstanding options or vesting of outstanding restricted stock units as described
  below, and (ii) serve as a post-effective amendment, pursuant to Rule 429 under the Securities Act, to our Registration Statement on Form
  S-8 (File No. 333-210627) filed with the Securities and Exchange Commission on April 6, 2016, and Form S-8 (File No. 333-197429) filed
  with the Securities and Exchange Commission on July 15, 2014 covering an aggregate of 6,009 for the purpose of adding a reoffer
  prospectus to each such registration statement as described below.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">This Registration Statement
  includes a reoffer prospectus prepared in accordance with the requirements of Part I of Form S-3 (in accordance with the General Instruction
  C to Form S-8). The reoffer prospectus covers reoffers and resales of shares of our common stock that have been or will be acquired by
  certain of our officers and directors (collectively, the &ldquo;selling stockholders&rdquo;) which may be deemed to be &ldquo;control
  securities&rdquo; and/or &ldquo;restricted securities&rdquo; (as such terms are defined in General Instruction C to Form S-8) of the
  Company.&nbsp;&nbsp;The reoffer prospectus relates to the resale of up to 294,117 shares of common stock that have been or may be issued
  to the selling stockholders pursuant to our stock option plans.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>
  
  <!-- Field: Page; Sequence: 2 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B>PART I</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B>INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Item 1.</B> <B>Plan Information.*</B></P>
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Item 2.</B> <B>Registrant Information and Employee Plan Annual Information.*</B></P>
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>
  
  
  
  
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 24px">*</TD>
      <TD STYLE="text-align: justify">Pursuant to the Note to Part I on Form S-8, the documents containing the information specified in
      Part I of this Registration Statement will be sent or given to plan participants as specified by Rule 428(b)(1) of the Securities
      Act of 1934, as amended, or the Securities Act. Such documents are not required to be filed, and are not filed, with the United States
      Securities and Exchange Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant
      to Rule 424 of the Securities Act. These documents and the documents incorporated by reference in this Registration Statement pursuant
      to Item 3 of Part II of this Form S-8, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the
      Securities Act.</TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>
  
  <!-- Field: Page; Sequence: 3 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>Reoffer Prospectus</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_001.jpg" ALT=""></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Up to 294,117 Shares of Common Stock under the AIkido
  Pharma, Inc. 2014 Equity Incentive Plan</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This reoffer prospectus is being
  used in connection with the offering from time to time by certain selling stockholders of AIkido, Inc., which we refer to herein as &ldquo;we,&rdquo;
  &ldquo;us,&rdquo; &ldquo;our&rdquo; or the &ldquo;Company,&rdquo; or their successors in interest of shares of our common stock, par value
  $0.0001 per share, which we refer to as the common stock, issued or to be issued, or which may be acquired upon the exercise of stock
  options or vesting of restricted stock units issued or to be issued, pursuant to our AIkido Pharma, Inc. 2014 Equity Incentive Plan, which
  we refer to herein as the 2014 Plan. The 2014 Plan is intended to provide incentives to attract, retain, and motivate highly competent
  persons such as officers, employees, directors, and consultants to our Company by providing them opportunities to acquire shares of our
  common stock. Additionally, the 2014 Plan is intended to assist in further aligning the interests of our officers, employees, directors
  and consultants to those of the Company&rsquo;s other stockholders.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The common stock may be sold
  from time to time by the selling stockholders or by their pledgees, donees, transferees or other successors in interest. Such sales may
  be made in the market on which our common stock is currently listed or otherwise at prices and at terms then prevailing or at prices
  related to the then current market price, or in negotiated transactions. The common stock may be sold by one or more of the following:
  (a) block trades in which the broker or dealer so engaged will attempt to sell the shares as agent but may position and resell portions
  of the block as principal to facilitate the transaction; (b) purchases by a broker or dealer as principal and resale by such broker or
  dealer for its account pursuant to this prospectus; (c) an exchange distribution in accordance with the rules of such exchange; and (d)
  ordinary brokerage transactions and transactions in which the broker solicits purchases. In effecting sales, brokers or dealers engaged
  by the selling stockholders may arrange for other brokers or dealers to participate. Brokers or dealers will receive commissions or discounts
  from selling stockholders in amounts to be negotiated immediately prior to the sale. Such brokers or dealers and any other participating
  brokers or dealers may be deemed to be &ldquo;underwriters&rdquo; within the meaning of the Securities Act, in connection with such sales.
  In addition, any securities covered by this prospectus which qualify for sale pursuant to Rule 144 may be sold under Rule 144 rather
  than pursuant to this prospectus. We will not receive any of the proceeds from the sale of these shares, although we have paid the expenses
  of preparing this prospectus and the related Registration Statement. If any additional options are issued to affiliates under the 2014
  Plan or otherwise, we may file with the Securities and Exchange Commission an update to this prospectus naming such person as a selling
  shareholder and indicating the number of shares such person is offering pursuant to the prospectus. See &ldquo;Selling Stockholders&rdquo;
  on page 15&nbsp;of this prospectus.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our common stock is&nbsp;listed
  on The Nasdaq Capital Market, or Nasdaq, under the ticker symbol &ldquo;AIKI.&rdquo; On September 2, 2022, the closing price of our common
  stock was $5.76.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Our principal executive offices
  are located at One Rockefeller Plaza, 11th Floor, New York, NY 10020 and our telephone number is (703) 992-9325.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>Investing in our common
  stock involves a high degree of risk. See the section entitled &ldquo;Risk Factors&rdquo; beginning on page 13&nbsp;and in the documents
  incorporated by reference herein before you decide to buy our common stock.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>Neither the Securities and
  Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus
  is truthful or complete. Any representation to the contrary is a criminal offense.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>The date of this prospectus is September 7, 2022</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>
  
  <!-- Field: Page; Sequence: 4 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B>TABLE OF CONTENTS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding-bottom: 1.5pt; width: 90%">&nbsp;</TD>
      <TD STYLE="padding-bottom: 1.5pt; width: 1%">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1.5pt solid; width: 9%; text-align: center"><B>Page No.</B></TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD><A HREF="#a_001">Cautionary Note on Forward Looking Statements</A></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">ii</TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD><A HREF="#a_002">Prospectus Summary</A></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">1</TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD><A HREF="#a_003">Risk Factors</A></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">13</TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD><A HREF="#a_004">Use of Proceeds</A></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">14</TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD><A HREF="#a_005">Selling Stockholders</A></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">15</TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD><A HREF="#a_006">Plan of Distribution</A></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">16</TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD><A HREF="#a_007">Legal Matters</A></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">17</TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD><A HREF="#a_008">Experts</A></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">17</TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD><A HREF="#a_009">Incorporation of Certain Documents By Reference</A></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">18</TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD><A HREF="#a_010">Where You Can Find More Information</A></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">19</TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD><A HREF="#a_011">Disclosure of Commission Position on Indemnification for Securities Law Violations</A></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">19</TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">You should rely only upon the
  information contained in this reoffer prospectus and the Registration Statement of which this reoffer prospectus is a part. We have not
  authorized any other person to provide you with different information. If anyone provides you with different or inconsistent information,
  you should not rely on it. We are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted.
  You should assume the information appearing in this reoffer prospectus is accurate only as of the date on the front cover of this reoffer
  prospectus. Our business, financial condition, results of operations and prospects may have changed since that date. This reoffer prospectus
  is based on information provided by us and other sources that we believe are reliable. We have summarized certain documents and other
  information in a manner we believe to be accurate, but we refer you to the actual documents for a more complete understanding of what
  we discuss in this reoffer prospectus. In making an investment decision, you must rely on your own examination of our business and the
  terms of the offering, including the merits and risks involved.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We obtained statistical data,
  market data and other industry data and forecasts used throughout, or incorporated by reference in, this reoffer prospectus from market
  research, publicly available information and industry publications. Industry publications generally state that they obtain their information
  from sources that they believe to be reliable, but they do not guarantee the accuracy and completeness of the information. Similarly,
  while we believe that the statistical data, industry data and forecasts and market research are reliable, we have not independently verified
  the data, and we do not make any representation as to the accuracy of the information. We have not sought the consent of the sources
  to refer to their reports appearing or incorporated by reference in this reoffer prospectus.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">This reoffer prospectus contains,
  or incorporates by reference, trademarks, tradenames, service marks and service names of AIkido Pharma, Inc. and other companies.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Unless the context otherwise
  requires, &ldquo;AIkido Pharma,&rdquo; &ldquo;AIKI,&rdquo; the &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our&rdquo;
  and similar names refer to AIkido Pharma, Inc. and its consolidated subsidiaries.&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>
  
  <!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B><A NAME="a_001"></A>CAUTIONARY NOTE ON FORWARD LOOKING STATEMENTS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">This reoffer prospectus and
  the documents incorporated by reference herein and therein may contain forward-looking statements that involve risks and uncertainties.
  All statements other than statements of historical fact contained in this reoffer prospectus and the documents incorporated by reference
  herein and therein, including statements regarding future events, our future financial performance, business strategy, and plans and
  objectives of management for future operations, are forward-looking statements. We have attempted to identify forward-looking statements
  by terminology including &ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo; &ldquo;can,&rdquo; &ldquo;continue,&rdquo; &ldquo;could,&rdquo;
  &ldquo;estimates,&rdquo; &ldquo;expects,&rdquo; &ldquo;intends,&rdquo; &ldquo;may,&rdquo; &ldquo;plans,&rdquo; &ldquo;potential,&rdquo;
  &ldquo;predicts,&rdquo; &ldquo;should,&rdquo; or &ldquo;will&rdquo; or the negative of these terms or other comparable terminology. Although
  we do not make forward looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy.
  These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks outlined
  under &ldquo;Risk Factors&rdquo; or elsewhere in this prospectus supplement, the accompanying prospectus and the documents incorporated
  by reference herein and therein, which may cause our or our industry&rsquo;s actual results, levels of activity, performance or achievements
  expressed or implied by these forward-looking statements. Moreover, we operate in a highly regulated, very competitive, and rapidly changing
  environment. New risks emerge from time to time and it is not possible for us to predict all risk factors, nor can we address the impact
  of all factors on our business or the extent to which any factor, or combination of factors, may cause our actual results to differ materially
  from those contained in any forward-looking statements. Risks that could affect our business also include the duration and scope of the
  COVID-19 pandemic and the impact on the demand for our technology; actions by governments, businesses and individuals taken in response
  to the pandemic; the length of time of the COVID-19 pandemic and the possibility of its reoccurrence; the timing required to develop
  effective treatments and a vaccine in the event of future outbreaks; the eventual impact of the pandemic and actions taken in response
  to the pandemic on global and regional economies; and the pace of recovery when the COVID-19 pandemic subsides.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We have based these forward-looking
  statements largely on our current expectations and projections about future events and financial trends that we believe may affect our
  financial condition, results of operations, business strategy, short term and long term business operations, and financial needs. These
  forward-looking statements are subject to certain risks and uncertainties that could cause our actual results to differ materially from
  those reflected in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited
  to, those discussed in this reoffer prospectus and the documents incorporated by reference herein, and in particular, the risks discussed
  below and under the heading &ldquo;Risk Factors&rdquo; and those discussed in other documents we file with the SEC. The following discussion
  should be read in conjunction with the financial statements for the fiscal years ended December 31, 2021 and 2020 and notes incorporated
  by reference therein. We undertake no obligation to revise or publicly release the results of any revision to these forward-looking statements,
  except as required by law. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed
  in this reoffer prospectus may not occur and actual results could differ materially and adversely from those anticipated or implied in
  the forward-looking statement.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">You should not place undue
  reliance on any forward-looking statement, each of which applies only as of the date of this reoffer prospectus. Except as required by
  law, we undertake no obligation to update or revise publicly any of the forward-looking statements after the date of this reoffer prospectus
  to conform our statements to actual results or changed expectations.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Any forward-looking statement
  you read in this reoffer prospectus or any document incorporated by reference herein or therein reflects our views at the time the forward-looking
  statement was made with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our
  operations, operating results, growth strategy and liquidity. You should not place undue reliance on these forward-looking statements
  because such statements speak only as to the date when made. We assume no obligation to publicly update or revise these forward-looking
  statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking
  statements, even if new information becomes available in the future, except as otherwise required by applicable law. You are advised,
  however, to consult any further disclosures we make on related subjects in our reports on Forms 10-Q, 8-K and 10-K filed with the SEC.
  You should understand that it is not possible to predict or identify all risk factors. Consequently, you should not consider any such
  list to be a complete set of all potential risks or uncertainties.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>
  
  <!-- Field: Page; Sequence: 6; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <DIV STYLE="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid">
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B><A NAME="a_002"></A>PROSPECTUS SUMMARY</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><I>The following summary highlights
  selected information contained or incorporated by reference in this reoffer prospectus. This summary does not contain all of the information
  you should consider before investing in the securities. Before making an investment decision, you should read the entire reoffer prospectus
  and any supplement hereto carefully, including the risk factors section as well as the financial statements and the notes to the financial
  statements incorporated herein by reference.</I></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><B>Business Overview</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">AIkido Pharma Inc., formerly
  known as Spherix Incorporated, was initially formed in 1967. Since 2017, the Company has operated as a biotechnology company with a diverse
  portfolio of small-molecule anticancer and antiviral therapeutics in development. The Company&rsquo;s pipeline consists of patented technology
  from leading universities and researchers. The Company&rsquo;s innovative therapeutic drug pipeline is currently being advanced through
  strong collaborations with renowned educational institutions, including the University of Texas at Austin, the University of Maryland,
  Baltimore and Wake Forest University. The Company&rsquo;s oncology therapeutics include prospective treatments for pancreatic cancer,
  acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The Company is also developing a broad-spectrum antiviral platform,
  in which the lead compounds have activity in cell-based assays against multiple viruses including Influenza virus, Ebolavirus and Marburg
  virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">As a result of the Company&rsquo;s
  biotechnology research and development and associated investments and acquisitions, its business portfolio now focuses on the treatment
  of three different cancers and multiple types of viral infections. The Company&rsquo;s pancreatic drug candidate, DHA-dFdC, developed
  at and licensed from the University of Texas at Austin, is a new compound that it hopes will become the next generation of chemotherapy
  treatment for advanced pancreatic cancer. DHA-dFdC overcomes tumor cell resistance to current chemotherapeutic drugs and is well tolerated
  in preclinical toxicity tests. Preclinical studies have also indicated that DHA-dFdC inhibits pancreatic cancer cell growth (up to 100,000-fold
  more potent that gemcitabine, a current standard therapy), accumulates preferentially in pancreatic tissue and has demonstrated activities
  against other cancers, including leukemia, lung and melanoma. The Company&rsquo;s AML and ALL compound, developed at the Wake Forest
  University, is a targeted therapeutic designed to overcome multiple resistance mechanisms observed with the current standard of care.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company previously focused
  its efforts on owning, developing, acquiring and monetizing intellectual property assets. Since May 2016, the Company has received limited
  funds from its intellectual property monetization. In addition to its patent monetization efforts, since the fourth quarter of 2017,
  the Company has been transitioning to focus its efforts as a technology and biotechnology development company. These efforts have focused
  on biotechnology research and blockchain technology research. The Company&rsquo;s biotechnology research development includes: (i) an
  investment in Hoth Therapeutics Inc. (&ldquo;Hoth&rdquo;), a development stage biopharmaceutical company focused on unique targeted therapeutics
  for patients suffering from indications such as atopic dermatitis, also known as eczema, (ii) an investment in DatChat, Inc. (&ldquo;DatChat&rdquo;),
  a privately held personal privacy platform focused on encrypted communication, internet security and digital rights management, and (iii)
  the acquisition of assets of CBM BioPharma, Inc. (&ldquo;CBM&rdquo;), a pharmaceutical company focusing on the development of cancer
  treatments.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In addition, the Company owns
  an exclusive world-wide license to patented technology from the University of Maryland Baltimore (&ldquo;UMB&rdquo;). Our license is
  for a broad spectrum antiviral drug platform. The licensed technology is a broadly acting pan-viral inhibitory compound with efficacy
  against multiple viral pathogens. The technology works to inhibit replication of multiple viruses including Influenza virus, SARS-CoV
  (coronavirus), MERS-CoV, Ebolavirus and Marburg virus. The technology is covered by two patent applications already on file with the
  United States Patent and Trademark Office. The UMB inventors are Drs. Matthew Frieman, Alexander MacKerell and Stuart Watson. The Company
  has also executed a Sponsored Research Agreement with UMB to support the development of the technology.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>
  
  </DIV>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>
  
  <!-- Field: Page; Sequence: 7; Options: NewSection; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <DIV STYLE="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid">
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><B>Our Products and Services</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The acquisition of the CBM
  assets has transformed the Company into an innovative pharmaceutical company dedicated to translating fundamental biological insights
  into new drugs and treatments that address unmet medical needs. Our drug platform focuses on the treatment of three cancers, including
  pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><B>Our Drug Platform</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">DHA-dFdC 4-(N)-Docosahexaenoyl
  2&acute;, 2&acute;-Difluorodeoxycytidine, referred to as DHA-dFdC, is patented technology licensed to the Company from the University
  of Texas at Austin. DHA-dFdC is a new compound poised to become the next generation of second-line chemotherapy treatment for advanced
  pancreatic cancer. DHA-dFdC overcomes tumor cell resistance to current chemotherapeutic drugs and is well tolerated in preclinical toxicity
  tests. Preclinical studies have also indicated that DHA-dFdC inhibits pancreatic cancer cell growth (up to 100,000-fold more potent that
  gemcitabine, a current standard therapy (for example, the IC50 value of DHA-dFdC is more than 100,000-fold smaller than gemcitabine),
  has documented efficacy against pancreatic tumors in a clinically relevant transgenic mouse model and has demonstrated activities against
  other cancer cell lines, including leukemia, lung and melanoma. Our AML and ALL compounds, developed at the Wake Forest University and
  called KPC34, are next generation targeted therapeutics designed to overcome multiple resistance mechanisms observed with the current
  standard of care. Combined, the Company&rsquo;s drug platform offers a robust drug pipeline focused on the development and commercialization
  of drugs to treat unmet medical needs in oncology. In addition, we are constantly seeking to grow our pipeline to treat unmet medical
  needs in oncology.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><B><I>Background*</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Pancreatic cancer is the 3rd
  leading cause of cancer-related death in the United States, surpassing breast cancer. It is expected to become the 2nd leading cause
  of cancer-related death in the United States by the year 2020, surpassing colorectal cancer. In fact, pancreatic cancer has the highest
  mortality rate of all major cancers. Approximately 91% of pancreatic cancer patients will die within five years of diagnosis, only 8%
  will survive more than five years and 74% of patients die within the first year of diagnosis.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Pancreatic cancer is one of
  the few cancers for which survival has not improved substantially over nearly 40 years. Treatment options for pancreatic cancer include
  surgery, radiation therapy and chemotherapy, which extend survival or relieve symptoms, but seldom produce a cure. Surgical removal of
  the tumor is possible in less than 20% of patients diagnosed with pancreatic cancer because detection is often in late stages and has
  spread beyond the pancreas. The current state of the art chemotherapy treatment is gemcitabine, Folfirinox cocktail or gemcitabine in
  combination with Abraxane.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">*</TD><TD STYLE="text-align: justify">Hirshberg Foundation for Pancreatic Cancer Research</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The University of Texas at
  Austin has identified a new drug, DHA-dFdC, that has shown positive results in preclinical studies, inhibiting pancreatic tumor growth
  in clinically relevant transgenic mouse models. In preclinical studies, DHA-dFdC has:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">inhibited pancreatic cancer cell growth (up to 100,000-fold
  more potent that gemcitabine, a current standard therapy);</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">has documented efficacy against pancreatic tumors in a clinically
  relevant transgenic mouse model;</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">has overcome tumor cell resistance to current chemotherapeutic
  drugs;</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">is well tolerated in preclinical toxicity test;</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">has demonstrated activities against other cancers (e.g. leukemia,
  lung, melanoma); and</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">may stimulate immunogenic cell death to activate host antitumor
  immunity.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>
  
  </DIV>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>
  
  <!-- Field: Page; Sequence: 8; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <DIV STYLE="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid">
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><B><I>Gem-DHA Technology Summary</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Gem-DHA is a conjugate molecule
  containing gemcitabine linked to a fatty acid called docosahexaenoic acid (DHA). The structure is:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_002.jpg" ALT=""></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><I>&nbsp;</I></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The DHA structure is illustrated
  above the dashed line in the graphic above and the gemcitabine structure is illustrated below the dashed line. The DHA patent states
  that Gem-DHA was more effective than gemcitabine alone in killing cancer cells in vitro and in vivo in a certain mouse model. The patent
  also states that conjugation of gemcitabine with fatty acids other than DHA did not increase effectiveness over gemcitabine.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><B><I>Gem-DHA Published Data</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The science behind Gem-DHA
  has been published in the following peer-reviewed scientific journals:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Naguib <I>et al</I>. (2016) Synthesis, characterization, and
  in vitro and in vivo evaluations of 4-(N)-docosahexaenoyl 2 &#769;, 2 &#769;- difluorodeoxycytidine with potent and broad-spectrum antitumor
  activity, NeoPlasia 18: 33-48.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Valdes <I>et al</I>. (2017) Preclinical evaluation of the
  short-term toxicity of 4-(N)-docosahexaenoyl 2 &#769;, 2 &#769;- difluorodeoxycytidine (DHA-dFdC), Pharm. Res. 34: 1224-1232.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Valdes <I>et al</I>. (2019) A solid lipid nanoparticle formulation
  of 4-(N)-docosahexaenoyl 2 &#769;, 2 &#769;- difluorodeoxycytidine with increased solubility, stability, and antitumor activity, Int.
  J. Pharm. 570:118609</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The portions of the published
  data state the following:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">The drug unexpectedly concentrates itself in the pancreas
  relative to other organs.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">It significantly increases the lifespan of mice with pancreatic
  cancer in either mice predisposed to develop the cancer, or into which human pancreatic cancer has been injected.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">It significantly decreases the growth of pancreatic tumors
  in mice, better than gemcitabine, the current standard of care.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">An oral formulation using lipid nanoparticles is highly effective
  and stable and has outstanding bioavailability.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></P>
  
  </DIV>
  
  <!-- Field: Page; Sequence: 9; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <DIV STYLE="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid">
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><B><I>Gem-DHA Patent Coverage</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Gem-DHA has one issued patent
  on the drug itself and one application on the oral formulation, as listed in the following table:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; border-bottom: black 1.5pt solid; width: 40%; text-align: left"><B>Number</B></TD>
      <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
      <TD STYLE="border-bottom: black 1.5pt solid; width: 9%; text-align: center"><B>Priority</B></TD>
      <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
      <TD STYLE="border-bottom: black 1.5pt solid; width: 9%; text-align: center"><B>Expiration</B></TD>
      <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
      <TD STYLE="width: 39%; border-bottom: black 1.5pt solid; text-align: center"><B>Title</B></TD></TR>
    <TR STYLE="vertical-align: top; background-color: #CCEEFF">
      <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">App. Serial No. 16/576,127, filed 9/19/2019 as continuation of App. Serial No. 15/115,393, filed 1/29/2015</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">1/29/2014</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">N/A</TD>
      <TD>&nbsp;</TD>
      <TD>Nucleobase Analogue Derivatives and Their Applications</TD></TR>
    <TR STYLE="vertical-align: top; background-color: white">
      <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">U.S. Patent No. 10,463,684, issued 11/5/2019 from App. Serial No. 15/115,393, filed 1/29/2015</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">1/29/2014</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">10/7/2035</TD>
      <TD>&nbsp;</TD>
      <TD>Nucleobase Analogue Derivatives and Their Applications</TD></TR>
    <TR STYLE="vertical-align: top; background-color: #CCEEFF">
      <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">Provisional App. Serial No. 62/858,114, filed 6/6/2019</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">6/6/2019</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">N/A</TD>
      <TD>&nbsp;</TD>
      <TD>Lipid Nanoparticles Containing Pharmaceutical and/or Nutraceutical agents and methods thereof</TD></TR>
    </TABLE>
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">All of this technology has
  been exclusively licensed to the Company for commercial development.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><B>AML &amp; ALL Cancer</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Our AML and ALL compounds,
  developed at the Wake Forest University and called KPC34, are next generation targeted therapeutics designed to overcome multiple resistance
  mechanisms observed with the current standard of care.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><B><I>Background</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Approximately 70% of all AML
  patients are over the age of 60 and only 6.6% of patients are still alive 5 years after diagnosis. Gemcitabine and Cytarabine are the
  backbone of AML and ALL therapy, but life expectancy is poor and relapses are much harder to treat.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Cytarabine (Ara-C) has been
  a major drug for acute myeloid leukemia (AML) treatment for more than three decades, but KPC34 has shown superior results when tested
  against Cytarabine.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></P>
  
  </DIV>
  
  <!-- Field: Page; Sequence: 10; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <DIV STYLE="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid">
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><B><I>KPC34 Technology Summary</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">KPC34, a conjugate molecule
  made of a gemcitabine molecule linked to a phospholipid, has the following structure:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_003.jpg" ALT=""></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Picture in the illustration
  above, to the left of the dashed line is the phospholipid portion and to the right of the dashed line is gemcitabine.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Gemcitabine is a chemotherapy
  drug used to treat a wide array of cancers, including breast cancer, ovarian cancer, non-small cell lung cancer, pancreatic cancer and
  bladder cancer. The drug interferes with DNA and its function of the phospholipid to which the gemcitabine is linked in KPC34, is to
  inhibit protein kinase C-type enzymes, which are involved in multiple signaling pathways in leukemia.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The strategy behind targeting
  both DNA synthesis and protein kinase C with one molecule is to double-target different mechanisms of action in leukemia cells and greatly
  reduce the possibility of development of resistance to the drug.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">KPC34 is intended to treat
  the relatively small population of patients with AML and acute ALL. In 2019, an estimated 21,450 people of all ages (11,650 men and boys
  and 9,800 women and girls) in the United States will be diagnosed with AML. AML is the second most common type of leukemia diagnosed
  in adults and children, but most cases occur in adults. AML makes up 32% of all adult leukemia cases (source: https://www.cancer.net/cancer-types/leukemia-acute-myeloid-aml/statistics).
  In 2019, an estimated 5,930 people of all ages (3,280 men and boys and 2,650 women and girls) in the United States were diagnosed with
  ALL (source: https://www.cancer.net/cancer-types/leukemia-acute-lymphocytic-all/statistics).</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The drug is intended for oral
  application, unlike standard chemotherapy drugs, which are given by injection.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Because of the low patient
  population, and the imminent expiration of the patent, FDA orphan drug status will be sought, which provides expedited review and seven
  years of exclusivity from approval of the new drug application.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Preliminary data from preclinical
  studies at Wake Forest on the drug includes the following results:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">kills leukemia cells in vitro;</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">inhibits protein kinase C in biochemical assays;</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">has efficacy against ALL in a mouse model when given orally;</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">has efficacy against central nervous system leukemia in a
  mouse model when given orally;</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">has efficacy against AML exhibiting phosphorylated protein
  kinase C in a mouse model when given orally;</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">based on the mouse models, Wake Forest claims KPC34 exhibited
  efficacy superior to gemcitabine alone or cytarabine (another chemo drug) alone; and</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">KPC34 also appears to overcome resistance to gemcitabine;
  it is effective against gemcitabine-resistant cancer.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The technology licensed is much broader than KPC34 represents, and
  includes both anticancer and antiviral conjugates, and could include a much broader range of indications, but we have no such drug candidates
  in development other than KPC34.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  </DIV>
  
  <!-- Field: Page; Sequence: 11; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <DIV STYLE="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid">
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B><I>KPC34 Patent Coverage</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The KPC34 license includes
  five issued patents, but only one of them covers KPC34. The patent is US7309696, entitled &ldquo;Compositions and methods for targeting
  cancer cells.&rdquo; It expires on August 11, 2021. All five of the licensed patents will expire by late 2022.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B><I>Licenses</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">On April 12, 2018, CBM entered
  into a patent license agreement (the &ldquo;UT Agreement&rdquo;) with the University of Texas at Austin on behalf of the Board of Regents
  of the University of Texas System. The UT Agreement granted to CBM an exclusive, royalty-bearing license to certain patent applications
  related to nucleobase analogue derivatives and their applications, and specifically to the DHA-dFdC drug candidate. On November 13, 2019,
  the University of Texas at Austin, the Company and CBM entered into an assignment of agreement, whereby CBM assigned all of its rights,
  title and interest to, and obligations under the UT Agreement to the Company.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">On April 17, 2018, CBM entered
  into a license agreement (the &ldquo;WF Agreement&rdquo;) with Wake Forest University Health Sciences (&ldquo;WF&rdquo;). The WF Agreement
  granted to CBM an exclusive, royalty-bearing license to WF&rsquo;s and The University of North Carolina at Chapel Hill&rsquo;s patents
  relating to the KPC34 drug candidate. On November 13, 2019, WF, the Company and CBM entered into an assignment of agreement, whereby
  CBM assigned all of its rights, title and interest to, and obligations under the WF Agreement to the Company.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">On April 13, 2020, the Company
  executed a Master License Agreement (the &ldquo;UMB License Agreement&rdquo;) with UMB. The UMB License Agreement covers certain antiviral
  compounds discovered by UMB. The compounds seek to inhibit replication of multiple viruses, including Influenza virus, SARS-CoV, MERS-CoV,
  Ebolavirus and Marburg virus. The technology is covered by two patent applications already on file with the United States Patent and
  Trademark Office. The UMB inventors are Drs. Matthew Frieman, Alexander MacKerell and Stuart Watson.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>Commercialization</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Our business success with
  our drug portfolio depends not only on the successful development and approval of the products but also on the commercialization. At
  present, our plan anticipates us making the investments necessary to build an in-house marketing and sales capability for the U.S. market
  for our drug pipeline, or to partner with a larger drug development company to commercialize our drugs as they move through the FDA approval
  process. As our drug compounds make their way through clinical development in the U.S., we intend to approach pharmaceutical and biotechnology
  companies outside the U.S. to negotiate and enter into strategic partnerships that will enable development and commercialization of our
  platform outside the U.S., where we believe the market opportunity is larger than that of the U.S. albeit far more complex to reach.
  We have no operations outside the U.S., nor are we planning to have any non-U.S. operations.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>Manufacturing and Supply</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">We do not have any manufacturing
  capabilities and therefore we will have to engage a third party to assist in manufacturing. Such manufacturing will need to be done in
  accordance with good manufacturing practice requirements (&ldquo;cGMP&rdquo;) regulations, to formulate and manufacture our product candidates.
  A list of third party manufacturers is currently being developed.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>
  
  </DIV>
  
  <!-- Field: Page; Sequence: 12; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <DIV STYLE="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid">
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>Government Regulation</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Governmental authorities
  in the U.S. and other countries extensively regulate the research, development, testing, manufacture, labeling, promotion, advertising,
  distribution and marketing of pharmaceutical products such as those being developed by us. In the U.S., the FDA regulates such products
  under the FDCA and implements related regulations. Failure to comply with applicable FDA requirements, both before and after approval,
  may subject us to administrative and judicial sanctions, such as a delay in approving or refusal by the FDA to approve pending applications,
  warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions and/or criminal
  prosecution.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>U.S. Food and Drug Administration
  Regulation</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B><I>United States Drug
  Development</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">In the United States, the
  FDA regulates drugs, medical devices and combinations of drugs and devices, or combination products, under the FDCA and its implementing
  regulations. Drugs are also subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals
  and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of
  substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development
  process, approval process or after approval, may subject an applicant to administrative or judicial sanctions. These sanctions could
  include, among other actions, the FDA&rsquo;s refusal to approve pending applications, withdrawal of an approval, a clinical hold, untitled
  or warning letters, requests for voluntary product recalls or withdrawals from the market, product seizures, total or partial suspension
  of production or distribution injunctions, fines, refusals of government contracts, restitution, disgorgement, or civil or criminal penalties.
  Any agency or judicial enforcement action could have a material adverse effect on us.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">completion of
                                              extensive pre-clinical laboratory tests, animal studies and formulation studies in accordance
                                              with applicable regulations, including the FDA&rsquo;s Good Laboratory Practice regulations;</TD>
  </TR></TABLE>
  
  <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">submission to
                                              the FDA of an IND, which must become effective before human clinical trials may begin;</TD>
  </TR></TABLE>
  
  <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">performance of
                                              adequate and well-controlled human clinical trials in accordance with an applicable IND and
                                              other clinical study related regulations, sometimes referred to as good clinical practices,
                                              or GCPs, to establish the safety and efficacy of the proposed drug for its proposed indication;</TD>
  </TR></TABLE>
  
  <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">submission to
                                              the FDA of an NDA;</TD>
  </TR></TABLE>
  
  <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">satisfactory completion
                                              of an FDA pre-approval inspection of the manufacturing facility or facilities at which the
                                              product, or components thereof, are produced to assess compliance with the FDA&rsquo;s cGMP
                                              requirements;</TD>
  </TR></TABLE>
  
  <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">potential FDA
                                              audit of the clinical trial sites that generated the data in support of the NDA; and</TD>
  </TR></TABLE>
  
  <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">FDA review and
                                              approval of the NDA prior to any commercial marketing or sale.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Once a pharmaceutical product
  candidate is identified for development, it enters the pre-clinical testing stage. Pre-clinical tests include laboratory evaluations
  of product chemistry, toxicity, formulation and stability, as well as animal studies. An IND sponsor must submit the results of the pre-clinical
  tests, together with manufacturing information, analytical data and any available clinical data or literature, to the FDA as part of
  the IND. The sponsor must also include a protocol detailing, among other things, the objectives of the initial clinical trial, the parameters
  to be used in monitoring safety and the effectiveness criteria to be evaluated if the initial clinical trial lends itself to an efficacy
  evaluation. Some pre-clinical testing may continue even after the IND is submitted. The IND automatically becomes effective 30 days after
  receipt by the FDA, unless the FDA raises concerns or questions related to a proposed clinical trial and places the trial on a clinical
  hold within that 30-day period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical
  trial can begin. Clinical holds also may be imposed by the FDA at any time before or during clinical trials due to safety concerns or
  non-compliance, and may be imposed on all drug products within a certain class of drugs. The FDA also can impose partial clinical holds,
  for example, prohibiting the initiation of clinical trials of a certain duration or for a certain dose.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>
  
  </DIV>
  
  <!-- Field: Page; Sequence: 13; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <DIV STYLE="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid">
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">All clinical trials must
  be conducted under the supervision of one or more qualified investigators in accordance with GCP regulations. These regulations include
  the requirement that all research subjects provide informed consent in writing before their participation in any clinical trial. Further,
  an IRB must review and approve the plan for any clinical trial before it commences at any institution, and the IRB must conduct continuing
  review and reapprove the study at least annually. An IRB considers, among other things, whether the risks to individuals participating
  in the clinical trial are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the information regarding
  the clinical trial and the consent form that must be provided to each clinical trial subject or his or her legal representative and must
  monitor the clinical trial until completed.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Each new clinical protocol
  and any amendments to the protocol must be submitted for FDA review, and to the IRBs for approval. Protocols detail, among other things,
  the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, and the parameters to be used to monitor
  subject safety.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Human clinical trials are
  typically conducted in three sequential phases that may overlap or be combined:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Phase 1. The product
                                              is initially introduced into a small number of healthy human subjects or patients and tested
                                              for safety, dosage tolerance, absorption, metabolism, distribution and excretion and, if
                                              possible, to gain early evidence on effectiveness. In the case of some products for severe
                                              or life-threatening diseases, especially when the product is suspected or known to be unavoidably
                                              toxic, the initial human testing may be conducted in patients.</TD>
  </TR></TABLE>
  
  <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Phase 2. Involves
                                              clinical trials in a limited patient population to identify possible adverse effects and
                                              safety risks, to preliminarily evaluate the efficacy of the product for specific targeted
                                              diseases and to determine dosage tolerance and optimal dosage and schedule.</TD>
  </TR></TABLE>
  
  <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Phase 3. Clinical
                                              trials are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded
                                              patient population at geographically dispersed clinical trial sites. These clinical trials
                                              are intended to establish the overall risk/benefit relationship of the product and provide
                                              an adequate basis for product labeling.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Post-approval trials, sometimes
  referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These studies are used to gain additional
  experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance
  of Phase 4 trials. Companies that conduct certain clinical trials also are required to register them and post the results of completed
  clinical trials on a government-sponsored database, such as ClinicalTrials.gov in the United States, within certain timeframes. Failure
  to do so can result in fines, adverse publicity and civil and criminal sanctions.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Progress reports detailing
  the results of the clinical trials, among other information, must be submitted at least annually to the FDA, and written IND safety reports
  must be submitted to the FDA and the investigators for serious and unexpected adverse events, findings from other studies that suggest
  a significant risk to humans exposed to the product, findings from animal or in vitro testing that suggest a significant risk to human
  subjects, and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol
  or investigator brochure. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period,
  if at all. The FDA or the clinical trial sponsor may suspend or terminate a clinical trial at any time on various grounds, including
  a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate
  approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&rsquo;s requirements
  or if the product has been associated with unexpected serious harm to patients. Additionally, some clinical trials are overseen by an
  independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee.
  This group provides authorization for whether a trial may move forward at designated check points based on access to certain data from
  the study. The clinical trial sponsor may also suspend or terminate a clinical trial based on evolving business objectives and/or competitive
  climate.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>
  
  </DIV>
  
  <!-- Field: Page; Sequence: 14; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <DIV STYLE="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid">
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Concurrent with clinical
  trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical
  characteristics of the product and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP
  requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among
  other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final product. Additionally,
  appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does
  not undergo unacceptable deterioration over its shelf life.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B><I>NDA and FDA Review
  Process</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The results of product development,
  pre-clinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the drug,
  proposed labeling and other relevant information, are submitted to the FDA as part of an NDA for a new drug, requesting approval to market
  the product. The submission of an NDA is subject to the payment of a substantial user fee, and the sponsor of an approved NDA is also
  subject to an annual program user fee; although a waiver of such fee may be obtained under certain limited circumstances. For example,
  the agency will waive the application fee for the first human drug application that a small business or its affiliate submits for review.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The FDA reviews all NDAs
  submitted before it accepts them for filing and may request additional information rather than accepting an NDA for filing. The FDA typically
  makes a decision on accepting an NDA for filing within 60 days of receipt. The decision to accept the NDA for filing means that the FDA
  has made a threshold determination that the application is sufficiently complete to permit a substantive review. Under the goals and
  policies agreed to by the FDA under the Prescription Drug User Fee Act (&ldquo;PDUFA&rdquo;), the FDA&rsquo;s goal to complete its substantive
  review of a standard NDA and respond to the applicant is ten months from the receipt of the NDA. The FDA does not always meet its PDUFA
  goal dates, and the review process is often significantly extended by FDA requests for additional information or clarification and may
  go through multiple review cycles.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">After the NDA submission
  is accepted for filing, the FDA reviews the NDA to determine, among other things, whether the proposed product is safe and effective
  for its intended use, and whether the product is being manufactured in accordance with cGMPs to assure and preserve the product&rsquo;s
  identity, strength, quality and purity. The FDA may refer applications for novel drug products or drug products which present difficult
  questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation
  and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations
  of an advisory committee, but it considers such recommendations carefully when making decisions. The FDA will likely re-analyze the clinical
  trial data, which could result in extensive discussions between the FDA and us during the review process. The review and evaluation of
  an NDA by the FDA is extensive and time consuming and may take longer than originally planned to complete, and we may not receive a timely
  approval, if at all.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Before approving an NDA,
  the FDA will conduct a pre-approval inspection of the manufacturing facilities for the new product to determine whether they comply with
  cGMPs. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with
  cGMP requirements and adequate to assure consistent production of the product within required specifications. In addition, before approving
  an NDA, the FDA may also audit data from clinical trials to ensure compliance with GCP requirements. After the FDA evaluates the application,
  manufacturing process and manufacturing facilities, it may issue an approval letter or a Complete Response Letter. An approval letter
  authorizes commercial marketing of the drug with specific prescribing information for specific indications. A Complete Response Letter
  indicates that the review cycle of the application is complete and the application will not be approved in its present form. A Complete
  Response Letter usually describes all the specific deficiencies in the NDA identified by the FDA. The Complete Response Letter may require
  additional clinical data and/or an additional pivotal Phase 3 clinical trial(s), and/or other significant and time-consuming requirements
  related to clinical trials, nonclinical studies or manufacturing. If a Complete Response Letter is issued, the applicant may either resubmit
  the NDA, addressing all the deficiencies identified in the letter, or withdraw the application. Even if such data and information are
  submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval. Data obtained from clinical trials
  are not always conclusive, and the FDA may interpret data differently than we interpret the same data.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>
  
  </DIV>
  
  <!-- Field: Page; Sequence: 15; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <DIV STYLE="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid">
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">There is no assurance that
  the FDA will ultimately approve a product for marketing in the United States, and we may encounter significant difficulties or costs
  during the review process. If a product receives marketing approval, the approval may be significantly limited to specific diseases and
  dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA
  may require that certain contraindications, warnings or precautions be included in the product labeling or may condition the approval
  of the NDA on other changes to the proposed labeling, development of adequate controls and specifications, or a commitment to conduct
  post-market testing or clinical trials and surveillance to monitor the effects of approved products. For example, the FDA may require
  Phase 4 clinical trials to further assess drug safety and effectiveness and may require testing and surveillance programs to monitor
  the safety of approved products that have been commercialized. The FDA may also place other conditions on approvals, including the requirement
  for a risk evaluation and mitigation strategy (&ldquo;REMS&rdquo;), to assure the safe use of the drug. If the FDA concludes a REMS is
  needed, the sponsor of the NDA must submit a proposed REMS; the FDA will not approve the NDA without an approved REMS, if required. A
  REMS could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution
  methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial
  promotion, distribution, prescription or dispensing of products. Product approvals may be withdrawn for non-compliance with regulatory
  requirements or if problems occur following initial marketing.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B><I>Reimbursement</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Potential sales of any of
  our product candidates, if approved, will depend, at least in part, on the extent to which such products will be covered by third-party
  payors, such as government health care programs, commercial insurance and managed healthcare organizations. These third-party payors
  are increasingly limiting coverage and/or reducing reimbursements for medical products and services. A third-party payor&rsquo;s decision
  to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Further, one payor&rsquo;s
  determination to provide coverage for a drug product does not assure that other payors will also provide coverage for the drug product.
  In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including
  price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment
  measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our future
  revenues and results of operations. Decreases in third-party reimbursement or a decision by a third-party payor to not cover a product
  candidate, if approved, or any future approved products could reduce physician usage of our products, and have a material adverse effect
  on our sales, results of operations and financial condition.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">In the United States, the
  Medicare Part D program provides a voluntary outpatient drug benefit to Medicare beneficiaries for certain products. We do not know whether
  our product candidates, if approved, will be eligible for coverage under Medicare Part D, but individual Medicare Part D plans offer
  coverage subject to various factors such as those described above. Furthermore, private payors often follow Medicare coverage policies
  and payment limitations in setting their own coverage policies.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B><I>Pediatric Exclusivity
  and Pediatric Use</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The Pediatric Research Equity
  Act, or PREA, requires a sponsor to conduct pediatric studies for most drugs and biologics, for a new active ingredient, new indication,
  new dosage form, new dosing regimen or new route of administration. Under PREA, original NDAs, biologics license applications and supplements
  thereto, must contain a pediatric assessment unless the sponsor has received a deferral or waiver. Unless otherwise required by regulation,
  PREA does not apply to any drug for an indication for which an orphan drug designation has been granted. The required assessment must
  assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and support dosing
  and administration for each pediatric subpopulation for which the product is safe and effective. The sponsor or FDA may request a deferral
  of pediatric studies for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding
  that the drug or biologic is ready for approval for use in adults before pediatric studies are complete or that additional safety or
  effectiveness data needs to be collected before the pediatric studies begin.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>
  
  </DIV>
  
  <!-- Field: Page; Sequence: 16; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <DIV STYLE="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid">
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Pediatric exclusivity is
  another type of non-patent marketing exclusivity in the United States and, if granted, provides for the attachment of an additional six
  months of marketing protection to the term of any existing regulatory exclusivity, including the non-patent and orphan exclusivity. This
  six-month exclusivity may be granted if an NDA sponsor submits pediatric data that fairly respond to a written request from the FDA for
  such data. The data does not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial
  is deemed to fairly respond to the FDA&rsquo;s request, the additional protection is granted. If reports of requested pediatric studies
  are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity or
  patent protection cover the product are extended by six months.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B><I>Healthcare Laws and
  Regulations</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Sales of our product candidates,
  if approved, or any other future product candidate will be subject to healthcare regulation and enforcement by the federal government
  and the states and foreign governments in which we might conduct our business. The healthcare laws and regulations that may affect our
  ability to operate include the following:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">The federal Anti-Kickback
                                              Statute makes it illegal for any person or entity to knowingly and willfully, directly or
                                              indirectly, solicit, receive, offer, or pay any remuneration that is in exchange for or to
                                              induce the referral of business, including the purchase, order, lease of any good, facility,
                                              item or service for which payment may be made under a federal healthcare program, such as
                                              Medicare or Medicaid. The term &ldquo;remuneration&rdquo; has been broadly interpreted to
                                              include anything of value.</TD>
  </TR></TABLE>
  
  <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Federal false
                                              claims and false statement laws, including the federal civil False Claims Act, prohibits,
                                              among other things, any person or entity from knowingly presenting, or causing to be presented,
                                              for payment to, or approval by, federal programs, including Medicare and Medicaid, claims
                                              for items or services, including drugs, that are false or fraudulent.</TD>
  </TR></TABLE>
  
  <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Health Insurance
                                              Portability and Accountability Act of 1996 (&ldquo;HIPAA&rdquo;) created additional federal
                                              criminal statutes that prohibit among other actions, knowingly and willfully executing, or
                                              attempting to execute, a scheme to defraud any healthcare benefit program, including private
                                              third-party payors or making any false, fictitious or fraudulent statement in connection
                                              with the delivery of or payment for healthcare benefits, items or services.</TD>
  </TR></TABLE>
  
  <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">HIPAA, as amended
                                              by the Health Information Technology for Economic and Clinical Health Act of 2009 and their
                                              implementing regulations, impose obligations on certain types of individuals and entities
                                              regarding the electronic exchange of information in common healthcare transactions, as well
                                              as standards relating to the privacy and security of individually identifiable health information.</TD>
  </TR></TABLE>
  
  <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">The federal Physician
                                              Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical
                                              supplies for which payment is available under Medicare, Medicaid or the Children&rsquo;s
                                              Health Insurance Program, with specific exceptions, to report annually to the Centers for
                                              Medicare &amp; Medicaid Services information related to payments or other transfers of value
                                              made to physicians and teaching hospitals, as well as ownership and investment interests
                                              held by physicians and their immediate family members.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Also, many states have similar
  laws and regulations, such as anti-kickback and false claims laws that may be broader in scope and may apply regardless of payor, in
  addition to items and services reimbursed under Medicaid and other state programs. Additionally, we may be subject to state laws that
  require pharmaceutical companies to comply with the federal government&rsquo;s and/or pharmaceutical industry&rsquo;s voluntary compliance
  guidelines, state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians
  and other healthcare providers or marketing expenditures, as well as state and foreign laws governing the privacy and security of health
  information, many of which differ from each other in significant ways and often are not preempted by HIPAA.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Additionally, to the extent
  that our product is sold in a foreign country, we may be subject to similar foreign laws.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><B>Corporate Information</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">We were incorporated in
  Delaware on May 1, 1992. Our principal executive offices are located at One Rockefeller Plaza, 11th Floor, New York, New York 10020,
  and our telephone number is (703) 992-9325. Our corporate website address is www.aikidopharma.com. The information contained on or accessible
  through our website is not a part of this prospectus, and the inclusion of our website address in this prospectus is an inactive textual
  reference only.&nbsp;</P>
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"></P>
  
  </DIV>
  
  <!-- Field: Page; Sequence: 17; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <DIV STYLE="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid">
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>The Offering</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 25%"><B>Outstanding Common Stock</B></TD>
      <TD STYLE="width: 75%; text-align: justify">As of September 2, 2022, there were&nbsp;5,485,096&nbsp;&nbsp;shares of common stock
  issued and outstanding.</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD><B>Common Stock Offered</B></TD>
      <TD STYLE="text-align: justify">Up to 294,117 shares of common stock for sale by the selling stockholders for their own account.</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD><B>Selling Stockholders</B></TD>
      <TD STYLE="text-align: justify">The selling stockholders are set forth in the Section entitled &ldquo;Selling Stockholders&rdquo; of
      this reoffer prospectus on page 15.</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD><B>Proceeds</B></TD>
      <TD STYLE="text-align: justify">We will not receive any proceeds from the sale of our common stock by the selling stockholders. We
      would, however, receive proceeds upon the exercise of the stock options by those who receive or received options under the 2014 Plan
      and exercise such options for cash. Any cash proceeds will be used by us for general corporate purposes.</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD><B>Risk Factors</B></TD>
      <TD STYLE="text-align: justify">The securities offered hereby involve a high degree of risk. See &ldquo;Risk Factors.&rdquo;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD><B>Nasdaq</B>&nbsp;<B>Symbol</B></TD>
      <TD>AIKI</TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Unless otherwise indicated, all share numbers in this registration
  statement takes into consideration all reverse stock splits effectuated by the Company since the inception of the 2014 Plan.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>
  
  </DIV>
  
  <!-- Field: Page; Sequence: 18; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="a_003"></A>RISK FACTORS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><I>Investing in our common
  stock involves risk. Before deciding whether to invest in our common stock, you should consider the risks, uncertainties and assumptions
  discussed under the heading </I>&ldquo;<I>Risk Factors</I>&rdquo; <I>in our Quarterly Reports on Form 10-Q for the fiscal quarters ended
  March 31, 2022 and June 30, 2022 and our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, each as incorporated
  by reference in this reoffer prospectus, any amendment or update thereto reflected in subsequent filings with the SEC, including in our
  annual reports on Form 10-K and quarterly reports on Form 10-Q, and all other information contained or incorporated by reference in this
  reoffer prospectus, as updated by our subsequent filings under the Securities and Exchange Act of 1934, as amended (referred to herein
  as the Exchange Act). There may be other unknown or unpredictable economic, business, competitive, regulatory or other factors that could
  have material adverse effects on our future results. If any of these risks actually occurs, our business, business prospects, financial
  condition or results of operations could be seriously harmed. This could cause the trading price of our common stock to decline, resulting
  in a loss of all or part of your investment. Please also read carefully the section above entitled </I>&ldquo;<I>Cautionary Note on Forward-Looking
  Statements.</I>&rdquo;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>
  
  <!-- Field: Page; Sequence: 19; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="a_004"></A>USE OF PROCEEDS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The shares which may
  be sold under this reoffer prospectus will be sold for the respective accounts of each of the selling stockholders listed herein (who
  are our executive officers and directors). Accordingly, we will not realize any proceeds from the sale of the shares of our common stock.
  We will receive proceeds from the exercise of the options; however, no assurance can be given as to when or if any or all of the options
  will be exercised. If any options are exercised, the proceeds derived therefrom will be used for working capital and general corporate
  purposes. All expenses of the registration of the shares will be paid by us. See &ldquo;Selling Stockholders&rdquo; and &ldquo;Plan of
  Distribution.&rdquo;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>
  
  <!-- Field: Page; Sequence: 20; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="a_005"></A>SELLING
  STOCKHOLDERS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">This reoffer prospectus
  relates to the shares of our common stock that are being registered for reoffers and resale by selling stockholders who have acquired
  or may acquire shares pursuant to the 2014 Plan. Offers and sales by selling stockholders who are our employees, consultants and &ldquo;affiliates&rdquo;
  (as such term is defined in Rule 405 under the Securities Act) are also covered by this reoffer prospectus.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The selling stockholders are our
  current directors, officers and affiliates who have acquired or may acquire in the future shares of our common stock under the 2014 Plan.
  The selling stockholders may, from time to time, resell all, a portion or none of the shares of our common stock covered by this reoffer
  prospectus. The following table sets forth information as of September 2, 2022 with respect to&nbsp;ownership of our common stock by each
  selling stockholder whose identity is known as of the date of this reoffer prospectus. There is no assurance that any of the selling stockholders
  will sell any or all of the shares offered by them under this Registration Statement. The address for each selling stockholders listed
  below is c/o AIkido Pharma, Inc., One Rockefeller Plaza, 11th Floor, New York, New York 10020.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Any changed information
  will be set forth in an amendment to the Registration Statement or supplement to this reoffer prospectus, to the extent required by law.
  Inclusion of an individual&rsquo;s name in the table below does not constitute an admission that such individual is an &ldquo;affiliate&rdquo;
  of the Company.</P>
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Name</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number&nbsp;of<BR> Shares<BR> Owned&nbsp;(1)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number&nbsp;of<BR> Shares&nbsp;to&nbsp;be<BR> Offered for<BR> the&nbsp;Account<BR> of&nbsp;the&nbsp;Selling<BR> Stockholder&nbsp;(2)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number&nbsp;of<BR> Shares&nbsp;to<BR> be&nbsp;Owned<BR> After<BR> Offering</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%&nbsp;Owned<BR> After<BR>
  Offering&nbsp;(3)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="width: 52%; text-align: left">Robert J. Vander Zanden (4) </TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">12,702</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">12,688</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">12,702</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="text-align: left">Anthony Hayes (5) </TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">84,016</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">82,043</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">84,016</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.56</TD><TD STYLE="text-align: left">%</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="text-align: left">Tim S. Ledwick (6) </TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,826</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,688</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,826</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="text-align: left">Paul LeMire (7) </TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,411</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,411</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,411</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="text-align: left">Robert Dudley (8) </TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,411</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,411</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,411</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="text-align: left">Gregory Blattner (9) </TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,411</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,411</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,411</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="text-align: left">Kyle Wool (10 ) </TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">80,058</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">80,058</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">80,058</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="width: 52%; text-align: left">Soo Yu (11)</TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">8,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">8,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">8,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="text-align: left">Christopher Devall (12)</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,068</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,068</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,068</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="text-align: left">Carlos Aldovero (13)</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
    </TABLE>
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0in"></TD><TD STYLE="width: 0.3in; text-align: left">*</TD><TD STYLE="text-align: justify">Less than 1%</TD>
  </TR></TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0in"></TD><TD STYLE="width: 0.3in; text-align: left">(1)</TD><TD STYLE="text-align: justify">Represents common stock owned on or about the date hereof by
  the Selling Stockholders and shares of common stock that are issued or to be issued, or which may be acquired upon the exercise of stock
  options issued or to be issued, or vesting of restricted stock awards issued or to be issued, pursuant to the 2014 Plan as of September 2, 2022.</TD>
  </TR></TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0in"></TD><TD STYLE="width: 0.3in; text-align: left">(2)</TD><TD STYLE="text-align: justify">Represents only shares of common stock that are issued or to
  be issued, or which may be acquired upon the exercise of stock options issued or to be issued, or vesting of restricted stock awards
  issued or to be issued, pursuant to the 2014 Plan. These shares constitute &ldquo;control securities&rdquo;&nbsp;as such term is defined
  in General Instruction C to Form S-8.</TD>
  </TR></TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0in"></TD><TD STYLE="width: 0.3in; text-align: left">(3)</TD><TD STYLE="text-align: justify">Percentage is computed with reference to  5,485,096 shares of our Common Stock outstanding as of
                                                                                 September 2, 2022 and assumes for each Selling Stockholder the sale of all shares offered by that particular Selling Stockholder
                                                                                 under the Prospectus.</TD>
  </TR></TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0in"></TD><TD STYLE="width: 0.3in; text-align: left">(4)</TD><TD STYLE="text-align: justify">Dr. Robert J. Vander Zanden is our Chairman of our Board and
  a member of our Board of Directors. The securities to be registered for resale by Mr. Zanden include 9,747 shares of common stock issued
  pursuant to the 2014 Plan and 2,941 shares of common stock issuable upon exercise of outstanding vested options issued pursuant to the
  2014 Plan.</TD>
  </TR></TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0in"></TD><TD STYLE="width: 0.3in; text-align: left">(5)</TD><TD STYLE="text-align: justify">Anthony Hayes is our Chief Executive Officer, Principal Accounting
  Officer, Principal Financial officer, and a member of our Board of Directors. The securities to be registered for resale by Mr. Hayes
  include 79,102 shares of common stock issued pursuant to the 2014 Plan and 2,941 shares of common stock issued upon exercise of outstanding
  vested options issued pursuant to the 2014 Plan.</TD>
  </TR></TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0in"></TD><TD STYLE="width: 0.3in; text-align: left">(6)</TD><TD STYLE="text-align: justify">Tim S. Ledwick a member of our Board of Directors. The securities
  to be registered for resale by Mr. Ledwick include 9,747 shares of common stock issued pursuant to the 2014 Plan and 2,941 shares of
  common stock issuable upon exercise of outstanding vested options issued pursuant to the 2014 Plan.</TD>
  </TR></TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0in"></TD><TD STYLE="width: 0.3in; text-align: left">(7)</TD><TD STYLE="text-align: justify">Gregory James Blattner is a member of our Board of Directors.
  The securities to be registered for resale by Mr. Blattner include 9,470 shares of common stock issued pursuant to the 2014 Plan and
  2,941 shares of common stock issuable upon exercise of outstanding vested options issued pursuant to the 2014 Plan.</TD>
  </TR></TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0in"></TD><TD STYLE="width: 0.3in; text-align: left">(8)</TD><TD STYLE="text-align: justify">Paul LeMire is a member of our Board of Directors. The securities
  to be registered for resale by Mr. LeMire include 9,470 shares of common stock issued pursuant to the 2014 Plan and 2,941 shares of common
  stock issuable upon exercise of outstanding vested options issued pursuant to the 2014 Plan.</TD>
  </TR></TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0in"></TD><TD STYLE="width: 0.3in; text-align: left">(9)</TD><TD STYLE="text-align: justify">Robert Dudley is a member of our Board of Directors. The securities
  to be registered for resale by Mr. Dudley include 9,470 shares of common stock issued pursuant to the 2014 Plan and 2,941 shares of common
  stock issuable upon exercise of outstanding vested options issued pursuant to the 2014 Plan.</TD>
  </TR></TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0in"></TD><TD STYLE="width: 0.3in; text-align: left">(10)</TD><TD STYLE="text-align: justify">Kyle Wool is a member of our Board of Directors. The securities
  to be registered for resale by Mr. Wool include 80,058 shares of common stock issued pursuant to the 2014 Plan.</TD>
  </TR></TABLE>
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 29px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11)</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soo Yu is a member of our Board of Directors. The securities to be registered for resale by Ms. Yu include 8,000 shares of common stock issued pursuant to the 2014 Plan.</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12)</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher Devall is our Vice President of Operations. The securities to be registered for resale by Mr. Devall include 8,068 shares of common stock issued pursuant to the 2014 Plan. </FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13)</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carlos Aldovero is the Chief Executive Officer of one of our subsidiaries. The securities to be registered for resale by Mr. Aldovero include 25,000 shares of common stock issued pursuant to the 2014 Plan. </FONT></TD></TR>
    </TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>
  
  <!-- Field: Page; Sequence: 21; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="a_006"></A>PLAN OF DISTRIBUTION</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">In this section of the
  reoffer prospectus, the term &ldquo;selling stockholder&rdquo; means and includes:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.5in">&nbsp;</TD>
      <TD STYLE="width: 0.25in">&#9679;</TD>
      <TD STYLE="text-align: justify">the persons identified in the table above as the selling stockholders;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&#9679;</TD>
      <TD STYLE="text-align: justify">those persons whose identities are not known as of the date hereof but may in the future be eligible
      to receive options under the 2014 Plan; and</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&#9679;</TD>
      <TD STYLE="text-align: justify">any of the purchasers, assignees, donees, pledgees, distributees, transferees or other successors
      in interest of those persons referenced above who may: (a) receive any of the shares of our common stock offered hereby after the
      date of this reoffer prospectus and (b) offer or sell those shares hereunder.</TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The shares of our common
  stock offered by this reoffer prospectus may be sold from time to time directly by the selling stockholders. Alternatively, the selling
  stockholders may from time to time offer such shares through underwriters, brokers, dealers, agents or other intermediaries. The selling
  stockholders as of the date of this reoffer prospectus have advised us that there were no underwriting or distribution arrangements entered
  into with respect to the common stock offered hereby. The distribution of the common stock by the selling stockholders may be effected:
  in one or more transactions that may take place on Nasdaq or any other stock exchange (including one or more block transaction) through
  customary brokerage channels, either through brokers acting as agents for the selling stockholders, or through market makers, dealers
  or underwriters acting as principals who may resell these shares on Nasdaq or any other stock exchange; in privately-negotiated sales;
  by a combination of such methods; or by other means. These transactions may be effected at market prices prevailing at the time of sale,
  at prices related to such prevailing market prices or at other negotiated prices. Usual and customary or specifically negotiated brokerage
  fees or commissions may be paid by the selling stockholders in connection with sales of our common stock.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The selling stockholders
  may enter into hedging transactions with broker-dealers in connection with distributions of the shares or otherwise. In such transactions,
  broker-dealers may engage in short sales of the shares of our common stock in the course of hedging the positions they assume with the
  selling stockholders. The selling stockholders also may sell shares short and redeliver the shares to close out such short positions.
  The selling stockholders may enter into option or other transactions with broker-dealers which require the delivery to the broker-dealer
  of shares of our common stock. The broker-dealer may then resell or otherwise transfer such shares of common stock pursuant to this reoffer
  prospectus.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The selling stockholders
  also may lend or pledge shares of our common stock to a broker-dealer. The broker-dealer may sell the shares of common stock so lent,
  or upon a default the broker-dealer may sell the pledged shares of common stock pursuant to this reoffer prospectus. Any securities covered
  by this reoffer prospectus which qualify for sale pursuant to Rule 144 may be sold under Rule 144 rather than pursuant to this reoffer
  prospectus.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The selling stockholders
  have advised us that they have not entered into any agreements, understandings or arrangements with any underwriters or broker-dealers
  regarding the sale of their securities. There is no underwriter or coordinating broker acting in connection with the proposed sale of
  shares of common stock the selling stockholders.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Although the shares of
  common stock covered by this reoffer prospectus are not currently being underwritten, the selling stockholders or their underwriters,
  brokers, dealers or other agents or other intermediaries, if any, that may participate with the selling security holders in any offering
  or distribution of common stock may be deemed &ldquo;underwriters&rdquo; within the meaning of the Securities Act and any profits realized
  or commissions received by them may be deemed underwriting compensation there under.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Under applicable rules
  and regulations under the Exchange Act, any person engaged in a distribution of shares of the common stock offered hereby may not simultaneously
  engage in market making activities with respect to the common stock for a period of up to five days preceding such distribution. The
  selling stockholders will be subject to the applicable provisions of the Exchange Act and the rules and regulations promulgated there
  under, including without limitation Regulation M, which provisions may limit the timing of purchases and sales by the selling stockholders.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">In order to comply with
  certain state securities or blue sky laws and regulations, if applicable, the common stock offered hereby will be sold in such jurisdictions
  only through registered or licensed brokers or dealers. In certain states, the common stock may not be sold unless they are registered
  or qualified for sale in such state, or unless an exemption from registration or qualification is available and is obtained.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">We will bear all costs,
  expenses and fees in connection with the registration of the common stock offered hereby. However, the selling stockholders will bear
  any brokerage or underwriting commissions and similar selling expenses, if any, attributable to the sale of the shares of common stock
  offered pursuant to this reoffer prospectus. We have agreed to indemnify certain of the selling security holders against certain liabilities,
  including liabilities under the Securities Act, or to contribute to payments to which any of those security holders may be required to
  make in respect thereof.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">There can be no assurance
  that the selling stockholders will sell any or all of the securities offered by them hereby.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>
  
  <!-- Field: Page; Sequence: 22; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="a_007"></A>LEGAL MATTERS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The validity of the securities
  being offered herein has been passed upon for us by Ellenoff Grossman&nbsp;&amp; Schole LLP, New York, New York.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="a_008"></A>EXPERTS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The consolidated financial
  statements of AIkido Pharma, Inc. as of and for the years ended December 31, 2021 and 2020 incorporated by reference in this Prospectus
  and in the Registration Statement have been so incorporated by reference in reliance on the report of WithumSmith+Brown PC and Marcum,
  LLP, independent registered public accounting firms, incorporated by reference herein, given on the authority of said firm as experts
  in auditing and accounting.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>
  
  <!-- Field: Page; Sequence: 23; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_009"></A>INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are &ldquo;incorporating
  by reference&rdquo; in this reoffer prospectus certain documents we file with the SEC, which means that we can disclose important information
  to you by referring you to those documents. The information in the documents incorporated by reference is considered to be part of this
  reoffer prospectus. Statements contained in documents that we file with the SEC and that are incorporated by reference in this reoffer
  prospectus will automatically update and supersede information contained in this reoffer prospectus, including information in previously
  filed documents or reports that have been incorporated by reference in this reoffer prospectus, to the extent the new information differs
  from or is inconsistent with the old information. We have filed the following documents with the SEC and they are incorporated herein
  by reference as of their respective dates of filing:&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.5in">&nbsp;</TD>
      <TD STYLE="width: 0.25in; text-align: justify">1.</TD>
      <TD STYLE="text-align: justify">Our Annual Report on <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/12239/000121390022015575/f10k2021_aikidopharma.htm">Form 10-K</A> for the year ended December 31, 2021 as filed with the SEC on March 28, 2022;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">2.</TD>
      <TD STYLE="text-align: justify">Our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2022 and June 30, 2022 as filed
      with the SEC on <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/12239/000121390022027192/f10q0322_aikidopharma.htm">May 16, 2022</A> and <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/12239/000121390022027192/f10q0322_aikidopharma.htm">August 12, 2022</A>, respectively;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">3.</TD>
      <TD STYLE="text-align: justify">Our Current Reports on Form 8-K and Form 8-K/A as filed with the SEC on <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/12239/000121390022003292/ea154427-8k_alkido.htm">January 24, 2022</A>, <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/12239/000121390022007037/ea155449-8k_aikido.htm">February 11, 2022</A>,&nbsp;<A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/12239/000121390022010395/ea156372-8k_aiki.htm">March 2, 2022</A>, <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/12239/000121390022016209/ea157188-8k_aikido.htm">March 30, 2022</A>, <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/12239/000121390022029547/ea160618-8k_aikido.htm">May 25, 2022</A>, <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/12239/000121390022032242/ea161453-8k_aikido.htm">June 10, 2022</A>, <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/12239/000121390022035403/ea162137-8k_aikido.htm">June 28, 2022</A>, <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/12239/000121390022037643/ea162506-8k_aikido.htm">July 6, 2022</A> and <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/12239/000121390022049761/ea164743-8k_aikido.htm">August 19, 2022</A>.&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">4.</TD>
      <TD STYLE="text-align: justify">Our definitive proxy statement <A HREF="http://www.sec.gov/Archives/edgar/data/12239/000121390022019253/def14a0422_aikidopharma.htm">Schedule 14A</A> filed with the SEC on April 12, 2022; and</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">5.</TD>
      <TD STYLE="text-align: justify">The description of the Company&rsquo;s securities registered under Section 12 of the Exchange Act
      as filed as <A HREF="http://www.sec.gov/Archives/edgar/data/12239/000141588914001204/ex4-1.htm">Exhibit 4.1</A> on Annual Report on Form 10-K for the year ended December 31, 2021 as filed with the SEC on March 28, 2022.</TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All reports and other documents
  (other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits filed in such forms that are related to such
  items unless such Form 8-K expressly provides to the contrary) we subsequently file pursuant to Section 13(a), 13(c), 14 or 15(d) of
  the Exchange Act, prior to the termination of this offering, will also be incorporated by reference in this reoffer prospectus and deemed
  to be part of this reoffer prospectus from the date of the filing of such reports and documents.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any statement contained in
  a document incorporated or deemed to be incorporated by reference in this reoffer prospectus shall be deemed modified, superseded or
  replaced for purposes of this reoffer prospectus to the extent that a statement contained in this reoffer prospectus, or in any subsequently
  filed document that also is deemed to be incorporated by reference in this reoffer prospectus, modifies, supersedes or replaces such
  statement. Any statement so modified, superseded or replaced shall not be deemed, except as so modified, superseded or replaced, to constitute
  a part of this reoffer prospectus. None of the information that we disclose under Items 2.02 or 7.01 of any Current Report on Form 8-K
  or any corresponding information, either furnished under Item 9.01 or included as an exhibit therein, that we may from time to time furnish
  to the SEC will be incorporated by reference into, or otherwise included in, this reoffer prospectus, except as otherwise expressly set
  forth in the relevant document. Subject to the foregoing, all information appearing in this reoffer prospectus is qualified in its entirety
  by the information appearing in the documents incorporated by reference.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You may request, orally or
  in writing, a copy of these documents, which will be provided to you at no cost (other than exhibits, unless such exhibits are specifically
  incorporated by reference), by contacting us at AIkido Pharma, Inc., One Rockefeller Plaza, 11th Floor, New York, New York 10020, Attention:
  Chief Financial Officer, or by telephone at (703) 992-9325. Information about us is also available at our website at www.aikidopharma.com.
  However, the information in our website is not a part of this reoffer prospectus and is not incorporated by reference.&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Page; Sequence: 24; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_010"></A>WHERE YOU CAN FIND MORE INFORMATION</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have filed a Registration
  Statement with the Securities and Exchange Commission under the Securities Act with respect to the shares of our common stock offered
  by this reoffer prospectus. This reoffer prospectus is part of that Registration Statement and does not contain all the information included
  in the Registration Statement. For further information with respect to our common stock and us, you should refer to the Registration
  Statement, its exhibits and the materials incorporated by reference therein. Portions of the exhibits have been omitted as permitted
  by the rules and regulations of the Securities and Exchange Commission. Statements made in this reoffer prospectus as to the contents
  of any contract, agreement or other document referred to are not necessarily complete. In each instance, we refer you to the copy of
  the contracts or other documents filed as exhibits to the Registration Statement, and these statements are hereby qualified in their
  entirety by reference to the contract or document. The Registration Statement may be inspected and copied at the public reference facilities
  maintained by the Securities and Exchange Commission at Room 1024, Judiciary Plaza, 100 F Street, N.E., Washington, D.C. 20549 and the
  Regional Offices at the Commission located in the Citicorp Center, 500 West Madison Street, Suite 1400, Chicago, Illinois 60661, and
  at 233 Broadway, New York, New York 10279. Copies of those filings can be obtained from the Commission&rsquo;s Public Reference Section,
  Judiciary Plaza, 100 F Fifth Street, N.E., Washington, D.C. 20549 at prescribed rates and may also be obtained from the web site that
  the Securities and Exchange Commission maintains at http://www.sec.gov. You may also call the Commission at 1-800-SEC-0330 for more information.
  We file annual, quarterly and current reports and other information with the Securities and Exchange Commission. You may read and copy
  any reports, statements or other information on file at the Commission&rsquo;s public reference room in Washington, D.C. You can request
  copies of those documents upon payment of a duplicating fee, by writing to the Securities and Exchange Commission.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_011"></A>DISCLOSURE OF COMMISSION POSITION ON</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INDEMNIFICATION FOR SECURITIES LAW VIOLATIONS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 145 of the Delaware
  General Corporation Law, or Delaware law, inter alia, empowers a Delaware corporation to indemnify any person who was or is a party or
  is threatened to be made a party to any threatened, pending or completed action, suit or proceeding (other than an action by or in the
  right of the corporation) by reason of the fact that such person is or was a director, officer, employee or agent of the corporation,
  or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation or other enterprise,
  against expenses (including attorneys&rsquo; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred
  by him in connection with such action, suit or proceeding if he acted in good faith and in a manner he reasonably believed to be in or
  not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause
  to believe his conduct was unlawful. Similar indemnity is authorized for such persons against expenses (including attorneys&rsquo; fees)
  actually and reasonably incurred in connection with the defense or settlement of any such threatened, pending or completed action or
  suit if such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation,
  and provided further that (unless a court of competent jurisdiction otherwise provides) such person shall not have been adjudged liable
  to the corporation. Any such indemnification may be made only as authorized in each specific case upon a determination by the stockholders
  or disinterested directors or by independent legal counsel in a written opinion that indemnification is proper because the indemnitee
  has met the applicable standard of conduct.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 145 further authorizes
  a corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the
  corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation
  or enterprise, against any liability asserted against him and incurred by him in any such capacity, or arising out of his status as such,
  whether or not the corporation would otherwise have the power to indemnify him under Section 145. We maintain policies insuring our officers
  and directors against certain liabilities for actions taken in such capacities, including liabilities under the Securities Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our amended and restated
  certificate of incorporation, as amended, and amended and restated bylaws require us to indemnify our directors to the fullest extent
  permitted under Delaware law or any other applicable law in effect, but if such statute or law is amended, we may change the standard
  of indemnification only to the extent that such amended statute or law permits us to provide broader indemnification rights to our directors.
  We must indemnify such officers and employees in the same manner and to the same extent that we are required to indemnify our directors
  under our amended and restated certificate of incorporation and amended and restated bylaws. Our amended and restated certificate of
  incorporation limits the personal liability of a director to us or our stockholders to damages for breach of the director&rsquo;s fiduciary
  duty. Pursuant to indemnification agreements we entered into with each of our directors, we are further required to indemnify our directors
  to the fullest extent permitted under Delaware law and our bylaws; provided that each such director shall enjoy the greater of (i) the
  advancement and indemnification rights permitted under our certificate of incorporation and bylaws for directors and officers as of the
  date of such indemnification agreement or (ii) the benefits so afforded by amendments thereto.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Insofar as indemnification
  for liabilities arising under the Securities Act of 1933, as amended, may be permitted to directors, officers or persons controlling
  us pursuant to the foregoing provisions, or otherwise, we have been advised that in the opinion of the Securities and Exchange Commission,
  such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Page; Sequence: 25; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>You should rely only on the information contained
  in this document. We have not authorized anyone to provide you with information that is different. This document may only be used where
  it is legal to sell these securities. The information in this document may only be accurate on the date of this document.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Additional risks and uncertainties not presently
  known may also impair our business operations. The risks and uncertainties described in this document and other risks and uncertainties
  which we may face in the future will have a greater impact on those who purchase our common stock. These purchasers will purchase our
  common stock at the market price or at a privately negotiated price and will run the risk of losing their entire investment.</B></P>
  
  <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Up to 294,117 Shares of Common Stock under the AIkido
  Pharma, Inc. 2014 Equity Incentive Plan</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>September 7, 2022</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Page; Sequence: 26 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART II</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; margin-left: 0in; text-indent: 0in; text-align: justify"><B>Item
  3. Incorporation of Documents by Reference.</B></P>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company hereby incorporates by reference into
  this Registration Statement the following documents previously filed with the SEC:&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.5in">&nbsp;</TD>
      <TD STYLE="width: 0.25in; text-align: justify">1.</TD>
      <TD STYLE="text-align: justify">Our Annual Report on <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/12239/000121390022015575/f10k2021_aikidopharma.htm">Form 10-K</A> for the year ended December 31, 2021 as filed with the SEC on March 28, 2022;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">2.</TD>
      <TD STYLE="text-align: justify">Our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2022 and June 30, 2022 as filed
      with the SEC on <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/12239/000121390022027192/f10q0322_aikidopharma.htm">May 16, 2022</A> and <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/12239/000121390022027192/f10q0322_aikidopharma.htm">August 12, 2022</A>, respectively;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">3.</TD>
      <TD STYLE="text-align: justify">Our Current Reports on Form 8-K and Form 8-K/A as filed with the SEC on <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/12239/000121390022003292/ea154427-8k_alkido.htm">January 24, 2022</A>, <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/12239/000121390022007037/ea155449-8k_aikido.htm">February 11, 2022</A>,&nbsp;<A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/12239/000121390022010395/ea156372-8k_aiki.htm">March 2, 2022</A>, <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/12239/000121390022016209/ea157188-8k_aikido.htm">March 30, 2022</A>, <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/12239/000121390022029547/ea160618-8k_aikido.htm">May 25, 2022</A>, <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/12239/000121390022032242/ea161453-8k_aikido.htm">June 10, 2022</A>, <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/12239/000121390022035403/ea162137-8k_aikido.htm">June 28, 2022</A>, <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/12239/000121390022037643/ea162506-8k_aikido.htm">July 6, 2022</A> and <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/12239/000121390022049761/ea164743-8k_aikido.htm">August 19, 2022</A>.&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">4.</TD>
      <TD STYLE="text-align: justify">Our definitive proxy statement <A HREF="http://www.sec.gov/Archives/edgar/data/12239/000121390022019253/def14a0422_aikidopharma.htm">Schedule 14A</A> filed with the SEC on April 12, 2022; and</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">5.</TD>
      <TD STYLE="text-align: justify">The description of the Company&rsquo;s securities registered under Section 12 of the Exchange Act
      as filed as <A HREF="http://www.sec.gov/Archives/edgar/data/12239/000141588914001204/ex4-1.htm">Exhibit 4.1</A> on Annual Report on Form 10-K for the year ended December 31, 2021 as filed with the SEC on March 28, 2022.</TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All reports and definitive
  proxy or information statements filed pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act (excluding any information furnished
  pursuant to Item 2.02 or Item 7.01 of any Current Report on Form 8-K) subsequent to the filing of this Registration Statement and prior
  to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which de-registers all
  securities then remaining unsold shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof
  from the date of filing such documents, except as to specific sections of such statements as set forth therein. Any statement contained
  in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes
  of this Registration Statement to the extent that a statement contained in any subsequently filed document which also is deemed to be
  incorporated by reference herein modifies or supersedes such statement.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; margin-left: 0in; text-indent: 0in; text-align: justify"><B>Item
  4. Description of Securities.</B></P>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; margin-left: 0in; text-indent: 0in; text-align: justify"><B>Item
  5. Interests of Named Experts and Counsel.</B></P>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The validity of the shares
  of common stock offered hereby will be passed upon by Ellenoff Grossman &amp; Schole LLP, counsel to the Registrant.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; margin-left: 0in; text-indent: 0in; text-align: justify"><B>Item
  6. Indemnification of Officers and Directors.</B></P>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 145 of the Delaware
  General Corporation Law, or Delaware law, inter alia, empowers a Delaware corporation to indemnify any person who was or is a party or
  is threatened to be made a party to any threatened, pending or completed action, suit or proceeding (other than an action by or in the
  right of the corporation) by reason of the fact that such person is or was a director, officer, employee or agent of the corporation,
  or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation or other enterprise,
  against expenses (including attorneys&rsquo; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred
  by him in connection with such action, suit or proceeding if he acted in good faith and in a manner he reasonably believed to be in or
  not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause
  to believe his conduct was unlawful. Similar indemnity is authorized for such persons against expenses (including attorneys&rsquo; fees)
  actually and reasonably incurred in connection with the defense or settlement of any such threatened, pending or completed action or
  suit if such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation,
  and provided further that (unless a court of competent jurisdiction otherwise provides) such person shall not have been adjudged liable
  to the corporation. Any such indemnification may be made only as authorized in each specific case upon a determination by the stockholders
  or disinterested directors or by independent legal counsel in a written opinion that indemnification is proper because the indemnitee
  has met the applicable standard of conduct.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Page; Sequence: 27; Options: NewSection; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 145 further authorizes
  a corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the
  corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation
  or enterprise, against any liability asserted against him and incurred by him in any such capacity, or arising out of his status as such,
  whether or not the corporation would otherwise have the power to indemnify him under Section 145. We maintain policies insuring our officers
  and directors against certain liabilities for actions taken in such capacities, including liabilities under the Securities Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our amended and restated
  certificate of incorporation and amended and restated bylaws require us to indemnify our directors to the fullest extent permitted under
  Delaware law or any other applicable law in effect, but if such statute or law is amended, we may change the standard of indemnification
  only to the extent that such amended statute or law permits us to provide broader indemnification rights to our directors. We must indemnify
  such officers and employees in the same manner and to the same extent that we are required to indemnify our directors under our amended
  and restated certificate of incorporation and amended and restated bylaws. Our amended and restated certificate of incorporation limits
  the personal liability of a director to us or our stockholders to damages for breach of the director&rsquo;s fiduciary duty. Pursuant
  to indemnification agreements we entered into with each of our directors, we are further required to indemnify our directors to the fullest
  extent permitted under Delaware law and our amended and restated bylaws; provided that each such director shall enjoy the greater of
  (i) the advancement and indemnification rights permitted under our amended and restated certificate of incorporation and amended and
  restated bylaws for directors and officers as of the date of such indemnification agreement or (ii) the benefits so afforded by amendments
  thereto.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; margin-left: 0in; text-indent: 0in; text-align: justify"><B>Item
  7. Exemption from Registration Claimed.</B></P>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">All shares of common stock registered
  hereunder for reoffer or resale have been or will be issued to our officers, directors, employees and consultants pursuant to the 2014
  Plan and a restrictive legend is placed on the certificates for the shares of common stock purchased and transfer stops are placed against
  such certificates. Such shares may only be reoffered and sold pursuant to registration under the Securities Act or pursuant to an applicable
  exemption under the Securities Act. As a result, such offers and sales are exempt from the registration requirements of the Securities
  Act pursuant to the provisions of Section&nbsp;4(a)(2) of the Securities Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; margin-left: 0in; text-indent: 0in; text-align: justify"><B>Item
  8. Exhibits.</B></P>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: Black 1.5pt solid; width: 9%"><B>Number</B></TD>
      <TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1.5pt solid; width: 90%; text-align: center"><B>Description</B></TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD>4.1</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/12239/000141588914002141/ex10-1.htm">AIkido Pharma, Inc. 2014 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 of the Registrant&rsquo;s Registration Statement on Form S-8 filed on July 15, 2014)</A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD>5.1</TD>
      <TD>&nbsp;</TD>
      <TD><A HREF="ea165377ex5-1_aikidopharma.htm">Opinion of Ellenoff Grossman &amp; Schole LLP (*)</A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD>5.2</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/12239/000141588914002141/ex5-1.htm">Opinion of Nixon Peabody LLP (incorporated by reference to Exhibit 5.1 of the Registrant&rsquo;s Registration Statement on Form S-8 filed on July 15, 2014)</A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD>23.1</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="ea165377ex5-1_aikidopharma.htm">Consent of Ellenoff Grossman &amp; Schole LLP (included in Exhibit 5.1)</A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD>23.2</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="ea165377ex23-2_aikidopharma.htm">Consent of WithumSmith+Brown, PC (*)</A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD>23.3</TD>
      <TD>&nbsp;</TD>
      <TD><A HREF="ea165377ex23-3_aikidopharma.htm">Consent of Marcum LLP (*)</A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD>24.1</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="#poa_001">Power of Attorney (included in the signature page to this Registration Statement)</A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD>107.1</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="ea165377ex-fee_aikidopharma.htm">Filing Fee Table (*)</A></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 24px">*</TD>
      <TD STYLE="text-align: justify">Filed herewith</TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Page; Sequence: 28; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; margin-left: 0in; text-indent: 0in; text-align: justify"><B>Item
  9. Undertakings.</B></P>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)
  The Registrant hereby undertakes:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(1) To
  file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i) To
  include any prospectus required by Section&nbsp;10(a)(3)&nbsp;of the Securities Act;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii) To
  reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective
  amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration
  Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities
  offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range
  may be reflected in the form of prospectus filed with the SEC pursuant to Rule&nbsp;424(b)&nbsp;if, in the aggregate, the changes in
  volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the &ldquo;Calculation
  of Registration Fee&rdquo; table in the effective Registration Statement;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii) To
  include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any
  material change to such information in the Registration Statement;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><I>Provided, however</I>, that
  paragraphs (a)(1)(a)&nbsp;and (a)(1)(b)&nbsp;do not apply if the Registration Statement is on Form&nbsp;S-8 and the information required
  to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the SEC
  by the Registrant pursuant to Section&nbsp;13 or 15(d)&nbsp;of the Exchange Act that are incorporated by reference in the Registration
  Statement.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(2) That,
  for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new
  Registration Statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to
  be the initial <I>bona fide </I>offering thereof.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(3) To
  remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination
  of the offering.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) The
  Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant&rsquo;s
  annual report pursuant to Section&nbsp;13(a)&nbsp;or 15(d)&nbsp;of the Exchange Act (and, where applicable, each filing of an employee
  benefit plan&rsquo;s annual report pursuant to Section&nbsp;15(d)&nbsp;of the Exchange Act) that is incorporated by reference in the
  Registration Statement shall be deemed to be a new Registration Statement relating to the securities offered therein, and the offering
  of such securities at that time shall be deemed to be the initial <I>bona fide </I>offering thereof.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) Insofar
  as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of
  the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such
  indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim
  for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer
  or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer
  or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the
  matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification
  by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Page; Sequence: 29; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="poa_001"></A>SIGNATURES</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements of
  the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for
  filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized,
  in the City of New York, State of New York, on September 7, 2022.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD COLSPAN="2"><B>AIKIDO PHARMA, INC.</B></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD COLSPAN="2">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">/s/ Anthony Hayes</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 60%">&nbsp;</TD>
      <TD STYLE="width: 5%">Name:&nbsp;</TD>
      <TD STYLE="width: 35%">Anthony Hayes</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>Title:</TD>
      <TD>Chief Executive Officer</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Principal Executive Officer,</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Principal Financial Officer and</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Principal Accounting Officer)</P></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>POWER OF ATTORNEY</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>KNOW ALL PERSONS BY THESE
  PRESENTS</B>, that each person whose signature appears below does hereby constitute and appoint Michael Rice with full power of substitution,
  such person&rsquo;s true and lawful attorneys-in-fact and agents for such person, with full power and authority to do any and all acts
  and things and to execute any and all instruments which said attorneys and agents, and any one of them, determine may be necessary or
  advisable or required to enable said corporation to comply with the Securities Act of 1933, as amended, and any rules or regulations
  or requirements of the Securities and Exchange Commission in connection with this Registration Statement. Without limiting the generality
  of the foregoing power and authority, the powers granted include the power and authority to sign the names of the undersigned officers
  and directors in the capacities indicated below to this Registration Statement, to any and all amendments, both pre-effective and post-effective,
  and supplements to this Registration Statement, and to any and all instruments or documents filed as part of or in conjunction with this
  Registration Statement or amendments or supplements thereof, and each of the undersigned hereby ratifies and confirms that all said attorneys
  and agents, or any one of them, shall do or cause to be done by virtue hereof. This Power of Attorney may be signed in several counterparts.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
  of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons on behalf of the Registrant
  in the capacities and on the dates indicated.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="width: 36%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signature</B></FONT></TD>
      <TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 42%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
      <TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 20%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT></TD></TR>
    <TR>
      <TD>&nbsp;</TD>
      <TD COLSPAN="2">&nbsp;</TD>
      <TD COLSPAN="2">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="vertical-align: top; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Anthony Hayes</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 7, 2022</FONT></TD></TR>
    <TR>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anthony Hayes</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(Principal Executive Officer,</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Principal Accounting Officer,</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Principal Financial Officer and Director)</P></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
    <TR>
      <TD>&nbsp;</TD>
      <TD COLSPAN="2">&nbsp;</TD>
      <TD COLSPAN="2">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="vertical-align: top; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Robert J. Vander Zanden</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director and Chairman of the Board of</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 7, 2022 </FONT></TD></TR>
    <TR>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert J. Vander Zanden</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="vertical-align: top; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Tim S. Ledwick</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 7, 2022</FONT></TD></TR>
    <TR>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tim S. Ledwick</FONT></TD>
      <TD COLSPAN="2">&nbsp;</TD>
      <TD COLSPAN="2">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="vertical-align: top; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Paul LeMire</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 7, 2022</FONT></TD></TR>
    <TR>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul LeMire</FONT></TD>
      <TD COLSPAN="2">&nbsp;</TD>
      <TD COLSPAN="2">&nbsp;</TD></TR>
    <TR>
      <TD>&nbsp;</TD>
      <TD COLSPAN="2">&nbsp;</TD>
      <TD COLSPAN="2">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="vertical-align: top; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Robert Dudley</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 7, 2022</FONT></TD></TR>
    <TR>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert Dudley</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
    <TR>
      <TD>&nbsp;</TD>
      <TD COLSPAN="2">&nbsp;</TD>
      <TD COLSPAN="2">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="vertical-align: top; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Gregory Blattner</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 7, 2022</FONT></TD></TR>
    <TR>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gregory Blattner</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="vertical-align: top; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Kyle Wool</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 7, 2022</FONT></TD></TR>
    <TR>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kyle Wool</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Soo Yu</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 7, 2022</FONT></TD></TR>
    <TR>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soo Yu</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
    </TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">II-4</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>
  
  
  
  
  
  
  </BODY>
  </HTML>
metadata_documents: [{"type": "S-8", "sequence": "1", "filename": "ea165377-s8_aikidopharma.htm", "description": "REGISTRATION STATEMENT", "secsgml_size_bytes": 231004}]
metadata_filer: {"company-data": {"conformed-name": "AIkido Pharma Inc.", "cik": "0000012239", "assigned-sic": "8731", "irs-number": "520849320", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-267318", "film-number": "221231792"}, "business-address": {"street1": "ONE ROCKEFELLER PLAZA, 11TH FLOOR", "city": "NEW YORK", "state": "NY", "zip": "10020", "phone": "347-321-7646"}, "mail-address": {"street1": "ONE ROCKEFELLER PLAZA, 11TH FLOOR", "city": "NEW YORK", "state": "NY", "zip": "10020"}, "former-company": [{"former-conformed-name": "Aikido Pharma Inc.", "date-changed": "20200317"}, {"former-conformed-name": "SPHERIX INC", "date-changed": "20010815"}, {"former-conformed-name": "BIOSPHERICS INC", "date-changed": "19920703"}]}
text: As filed with the Securities and Exchange Commission
  on September 7, 2022
  Registration No.
  333-
  UNITED STATES
  SECURITIES AND EXCHANGE
  COMMISSION
  Washington, D.C. 20549
  FORM S-8
  REGISTRATION STATEMENT
  UNDER THE SECURITIES ACT OF 1933
  AIkido Pharma, Inc.
  (Exact Name of Registrant
  as Specified in its Charter)
  Delaware
  52-0849320
  (State or Other Jurisdiction of
  Incorporation or Organization)
  (I.R.S. Employer
  Identification No.)
  One Rockefeller Plaza,
  11
  th
  Floor
  New York, NY 10020
  (Address of Principal Executive
  Offices) (Zip Code)
  AIkido Pharma, Inc. 2014 Equity Incentive Plan
  (Full Title of the Plan)
  Anthony Hayes
  Chief Executive Officer
  One Rockefeller Plaza,
  11
  th
  Floor
  New York, NY 10020
  (Name and Address of Agent
  for Service)
  (703) 992-9325
  (Telephone Number, including
  area code, of agent for service)
  Copies to:
  Robert F. Charron, Esq.
  Sarah Williams, Esq.
  Ellenoff Grossman &
  Schole LLP
  1345 Avenue of Americas,
  11th Floor
  New York, New York 10105
  (212) 370-1300
  Fax: (212) 370-7889
  Indicate by check mark whether the Registrant
  is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company.
  See definitions of
  "
  large accelerated filer,
  " "
  accelerated filer,
  " "
  smaller reporting
  company
  "
  and
  "
  emerging growth company
  "
  in Rule 12b-2 of the Exchange Act.
  Large accelerated filer
  ☐
  Accelerated filer
  ☐
  Non-accelerated filer
  ☑
  Smaller reporting company
  ☑
  Emerging growth company
  ☐
  If an emerging growth company, indicate by check
  mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
  standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.
  ☐
  Explanatory Note
  This Registration Statement on
  Form S-8 of AIkido Pharma, Inc. ("we," "us," "our" or the "Company") has been prepared
  in accordance with the requirements of Form S-8 under the Securities Act of 1933, as amended (the "Securities Act"), to (i)
  register 288,108 shares of our common stock, par value $0.0001 per share, to be issued pursuant to the AIkido Pharma, Inc. 2014 Equity
  Incentive Plan, as described in more detail herein, including registering for resale pursuant to a reoffer prospectus certain securities
  to be issued to our officers and directors upon exercise of outstanding options or vesting of outstanding restricted stock units as described
  below, and (ii) serve as a post-effective amendment, pursuant to Rule 429 under the Securities Act, to our Registration Statement on Form
  S-8 (File No. 333-210627) filed with the Securities and Exchange Commission on April 6, 2016, and Form S-8 (File No. 333-197429) filed
  with the Securities and Exchange Commission on July 15, 2014 covering an aggregate of 6,009 for the purpose of adding a reoffer
  prospectus to each such registration statement as described below.
  This Registration Statement
  includes a reoffer prospectus prepared in accordance with the requirements of Part I of Form S-3 (in accordance with the General Instruction
  C to Form S-8). The reoffer prospectus covers reoffers and resales of shares of our common stock that have been or will be acquired by
  certain of our officers and directors (collectively, the "selling stockholders") which may be deemed to be "control
  securities" and/or "restricted securities" (as such terms are defined in General Instruction C to Form S-8) of the
  Company.  The reoffer prospectus relates to the resale of up to 294,117 shares of common stock that have been or may be issued
  to the selling stockholders pursuant to our stock option plans.
  PART I
  INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
  Item 1.
  Plan Information.*
  Item 2.
  Registrant Information and Employee Plan Annual Information.*
  *
  Pursuant to the Note to Part I on Form S-8, the documents containing the information specified in
      Part I of this Registration Statement will be sent or given to plan participants as specified by Rule 428(b)(1) of the Securities
      Act of 1934, as amended, or the Securities Act. Such documents are not required to be filed, and are not filed, with the United States
      Securities and Exchange Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant
      to Rule 424 of the Securities Act. These documents and the documents incorporated by reference in this Registration Statement pursuant
      to Item 3 of Part II of this Form S-8, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the
      Securities Act.
  Reoffer Prospectus
  Up to 294,117 Shares of Common Stock under the AIkido
  Pharma, Inc. 2014 Equity Incentive Plan
  This reoffer prospectus is being
  used in connection with the offering from time to time by certain selling stockholders of AIkido, Inc., which we refer to herein as "we,"
  "us," "our" or the "Company," or their successors in interest of shares of our common stock, par value
  $0.0001 per share, which we refer to as the common stock, issued or to be issued, or which may be acquired upon the exercise of stock
  options or vesting of restricted stock units issued or to be issued, pursuant to our AIkido Pharma, Inc. 2014 Equity Incentive Plan, which
  we refer to herein as the 2014 Plan. The 2014 Plan is intended to provide incentives to attract, retain, and motivate highly competent
  persons such as officers, employees, directors, and consultants to our Company by providing them opportunities to acquire shares of our
  common stock. Additionally, the 2014 Plan is intended to assist in further aligning the interests of our officers, employees, directors
  and consultants to those of the Company's other stockholders.
  The common stock may be sold
  from time to time by the selling stockholders or by their pledgees, donees, transferees or other successors in interest. Such sales may
  be made in the market on which our common stock is currently listed or otherwise at prices and at terms then prevailing or at prices
  related to the then current market price, or in negotiated transactions. The common stock may be sold by one or more of the following:
  (a) block trades in which the broker or dealer so engaged will attempt to sell the shares as agent but may position and resell portions
  of the block as principal to facilitate the transaction; (b) purchases by a broker or dealer as principal and resale by such broker or
  dealer for its account pursuant to this prospectus; (c) an exchange distribution in accordance with the rules of such exchange; and (d)
  ordinary brokerage transactions and transactions in which the broker solicits purchases. In effecting sales, brokers or dealers engaged
  by the selling stockholders may arrange for other brokers or dealers to participate. Brokers or dealers will receive commissions or discounts
  from selling stockholders in amounts to be negotiated immediately prior to the sale. Such brokers or dealers and any other participating
  brokers or dealers may be deemed to be "underwriters" within the meaning of the Securities Act, in connection with such sales.
  In addition, any securities covered by this prospectus which qualify for sale pursuant to Rule 144 may be sold under Rule 144 rather
  than pursuant to this prospectus. We will not receive any of the proceeds from the sale of these shares, although we have paid the expenses
  of preparing this prospectus and the related Registration Statement. If any additional options are issued to affiliates under the 2014
  Plan or otherwise, we may file with the Securities and Exchange Commission an update to this prospectus naming such person as a selling
  shareholder and indicating the number of shares such person is offering pursuant to the prospectus. See "Selling Stockholders"
  on page 15 of this prospectus.
  Our common stock is listed
  on The Nasdaq Capital Market, or Nasdaq, under the ticker symbol "AIKI." On September 2, 2022, the closing price of our common
  stock was $5.76.
  Our principal executive offices
  are located at One Rockefeller Plaza, 11th Floor, New York, NY 10020 and our telephone number is (703) 992-9325.
  Investing in our common
  stock involves a high degree of risk. See the section entitled "Risk Factors" beginning on page 13 and in the documents
  incorporated by reference herein before you decide to buy our common stock.
  Neither the Securities and
  Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus
  is truthful or complete. Any representation to the contrary is a criminal offense.
  The date of this prospectus is September 7, 2022
  TABLE OF CONTENTS
  Page No.
  Cautionary Note on Forward Looking Statements
  ii
  Prospectus Summary
  1
  Risk Factors
  13
  Use of Proceeds
  14
  Selling Stockholders
  15
  Plan of Distribution
  16
  Legal Matters
  17
  Experts
  17
  Incorporation of Certain Documents By Reference
  18
  Where You Can Find More Information
  19
  Disclosure of Commission Position on Indemnification for Securities Law Violations
  19
  You should rely only upon the
  information contained in this reoffer prospectus and the Registration Statement of which this reoffer prospectus is a part. We have not
  authorized any other person to provide you with different information. If anyone provides you with different or inconsistent information,
  you should not rely on it. We are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted.
  You should assume the information appearing in this reoffer prospectus is accurate only as of the date on the front cover of this reoffer
  prospectus. Our business, financial condition, results of operations and prospects may have changed since that date. This reoffer prospectus
  is based on information provided by us and other sources that we believe are reliable. We have summarized certain documents and other
  information in a manner we believe to be accurate, but we refer you to the actual documents for a more complete understanding of what
  we discuss in this reoffer prospectus. In making an investment decision, you must rely on your own examination of our business and the
  terms of the offering, including the merits and risks involved.
  We obtained statistical data,
  market data and other industry data and forecasts used throughout, or incorporated by reference in, this reoffer prospectus from market
  research, publicly available information and industry publications. Industry publications generally state that they obtain their information
  from sources that they believe to be reliable, but they do not guarantee the accuracy and completeness of the information. Similarly,
  while we believe that the statistical data, industry data and forecasts and market research are reliable, we have not independently verified
  the data, and we do not make any representation as to the accuracy of the information. We have not sought the consent of the sources
  to refer to their reports appearing or incorporated by reference in this reoffer prospectus.
  This reoffer prospectus contains,
  or incorporates by reference, trademarks, tradenames, service marks and service names of AIkido Pharma, Inc. and other companies.
  Unless the context otherwise
  requires, "AIkido Pharma," "AIKI," the "Company," "we," "us," "our"
  and similar names refer to AIkido Pharma, Inc. and its consolidated subsidiaries.
  i
  CAUTIONARY NOTE ON FORWARD LOOKING STATEMENTS
  This reoffer prospectus and
  the documents incorporated by reference herein and therein may contain forward-looking statements that involve risks and uncertainties.
  All statements other than statements of historical fact contained in this reoffer prospectus and the documents incorporated by reference
  herein and therein, including statements regarding future events, our future financial performance, business strategy, and plans and
  objectives of management for future operations, are forward-looking statements. We have attempted to identify forward-looking statements
  by terminology including "anticipates," "believes," "can," "continue," "could,"
  "estimates," "expects," "intends," "may," "plans," "potential,"
  "predicts," "should," or "will" or the negative of these terms or other comparable terminology. Although
  we do not make forward looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy.
  These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks outlined
  under "Risk Factors" or elsewhere in this prospectus supplement, the accompanying prospectus and the documents incorporated
  by reference herein and therein, which may cause our or our industry's actual results, levels of activity, performance or achievements
  expressed or implied by these forward-looking statements. Moreover, we operate in a highly regulated, very competitive, and rapidly changing
  environment. New risks emerge from time to time and it is not possible for us to predict all risk factors, nor can we address the impact
  of all factors on our business or the extent to which any factor, or combination of factors, may cause our actual results to differ materially
  from those contained in any forward-looking statements. Risks that could affect our business also include the duration and scope of the
  COVID-19 pandemic and the impact on the demand for our technology; actions by governments, businesses and individuals taken in response
  to the pandemic; the length of time of the COVID-19 pandemic and the possibility of its reoccurrence; the timing required to develop
  effective treatments and a vaccine in the event of future outbreaks; the eventual impact of the pandemic and actions taken in response
  to the pandemic on global and regional economies; and the pace of recovery when the COVID-19 pandemic subsides.
  We have based these forward-looking
  statements largely on our current expectations and projections about future events and financial trends that we believe may affect our
  financial condition, results of operations, business strategy, short term and long term business operations, and financial needs. These
  forward-looking statements are subject to certain risks and uncertainties that could cause our actual results to differ materially from
  those reflected in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited
  to, those discussed in this reoffer prospectus and the documents incorporated by reference herein, and in particular, the risks discussed
  below and under the heading "Risk Factors" and those discussed in other documents we file with the SEC. The following discussion
  should be read in conjunction with the financial statements for the fiscal years ended December 31, 2021 and 2020 and notes incorporated
  by reference therein. We undertake no obligation to revise or publicly release the results of any revision to these forward-looking statements,
  except as required by law. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed
  in this reoffer prospectus may not occur and actual results could differ materially and adversely from those anticipated or implied in
  the forward-looking statement.
  You should not place undue
  reliance on any forward-looking statement, each of which applies only as of the date of this reoffer prospectus. Except as required by
  law, we undertake no obligation to update or revise publicly any of the forward-looking statements after the date of this reoffer prospectus
  to conform our statements to actual results or changed expectations.
  Any forward-looking statement
  you read in this reoffer prospectus or any document incorporated by reference herein or therein reflects our views at the time the forward-looking
  statement was made with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our
  operations, operating results, growth strategy and liquidity. You should not place undue reliance on these forward-looking statements
  because such statements speak only as to the date when made. We assume no obligation to publicly update or revise these forward-looking
  statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking
  statements, even if new information becomes available in the future, except as otherwise required by applicable law. You are advised,
  however, to consult any further disclosures we make on related subjects in our reports on Forms 10-Q, 8-K and 10-K filed with the SEC.
  You should understand that it is not possible to predict or identify all risk factors. Consequently, you should not consider any such
  list to be a complete set of all potential risks or uncertainties.
  ii
  PROSPECTUS SUMMARY
  The following summary highlights
  selected information contained or incorporated by reference in this reoffer prospectus. This summary does not contain all of the information
  you should consider before investing in the securities. Before making an investment decision, you should read the entire reoffer prospectus
  and any supplement hereto carefully, including the risk factors section as well as the financial statements and the notes to the financial
  statements incorporated herein by reference.
  Business Overview
  AIkido Pharma Inc., formerly
  known as Spherix Incorporated, was initially formed in 1967. Since 2017, the Company has operated as a biotechnology company with a diverse
  portfolio of small-molecule anticancer and antiviral therapeutics in development. The Company's pipeline consists of patented technology
  from leading universities and researchers. The Company's innovative therapeutic drug pipeline is currently being advanced through
  strong collaborations with renowned educational institutions, including the University of Texas at Austin, the University of Maryland,
  Baltimore and Wake Forest University. The Company's oncology therapeutics include prospective treatments for pancreatic cancer,
  acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The Company is also developing a broad-spectrum antiviral platform,
  in which the lead compounds have activity in cell-based assays against multiple viruses including Influenza virus, Ebolavirus and Marburg
  virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19.
  As a result of the Company's
  biotechnology research and development and associated investments and acquisitions, its business portfolio now focuses on the treatment
  of three different cancers and multiple types of viral infections. The Company's pancreatic drug candidate, DHA-dFdC, developed
  at and licensed from the University of Texas at Austin, is a new compound that it hopes will become the next generation of chemotherapy
  treatment for advanced pancreatic cancer. DHA-dFdC overcomes tumor cell resistance to current chemotherapeutic drugs and is well tolerated
  in preclinical toxicity tests. Preclinical studies have also indicated that DHA-dFdC inhibits pancreatic cancer cell growth (up to 100,000-fold
  more potent that gemcitabine, a current standard therapy), accumulates preferentially in pancreatic tissue and has demonstrated activities
  against other cancers, including leukemia, lung and melanoma. The Company's AML and ALL compound, developed at the Wake Forest
  University, is a targeted therapeutic designed to overcome multiple resistance mechanisms observed with the current standard of care.
  The Company previously focused
  its efforts on owning, developing, acquiring and monetizing intellectual property assets. Since May 2016, the Company has received limited
  funds from its intellectual property monetization. In addition to its patent monetization efforts, since the fourth quarter of 2017,
  the Company has been transitioning to focus its efforts as a technology and biotechnology development company. These efforts have focused
  on biotechnology research and blockchain technology research. The Company's biotechnology research development includes: (i) an
  investment in Hoth Therapeutics Inc. ("Hoth"), a development stage biopharmaceutical company focused on unique targeted therapeutics
  for patients suffering from indications such as atopic dermatitis, also known as eczema, (ii) an investment in DatChat, Inc. ("DatChat"),
  a privately held personal privacy platform focused on encrypted communication, internet security and digital rights management, and (iii)
  the acquisition of assets of CBM BioPharma, Inc. ("CBM"), a pharmaceutical company focusing on the development of cancer
  treatments.
  In addition, the Company owns
  an exclusive world-wide license to patented technology from the University of Maryland Baltimore ("UMB"). Our license is
  for a broad spectrum antiviral drug platform. The licensed technology is a broadly acting pan-viral inhibitory compound with efficacy
  against multiple viral pathogens. The technology works to inhibit replication of multiple viruses including Influenza virus, SARS-CoV
  (coronavirus), MERS-CoV, Ebolavirus and Marburg virus. The technology is covered by two patent applications already on file with the
  United States Patent and Trademark Office. The UMB inventors are Drs. Matthew Frieman, Alexander MacKerell and Stuart Watson. The Company
  has also executed a Sponsored Research Agreement with UMB to support the development of the technology.
  1
  Our Products and Services
  The acquisition of the CBM
  assets has transformed the Company into an innovative pharmaceutical company dedicated to translating fundamental biological insights
  into new drugs and treatments that address unmet medical needs. Our drug platform focuses on the treatment of three cancers, including
  pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).
  Our Drug Platform
  DHA-dFdC 4-(N)-Docosahexaenoyl
  2´, 2´-Difluorodeoxycytidine, referred to as DHA-dFdC, is patented technology licensed to the Company from the University
  of Texas at Austin. DHA-dFdC is a new compound poised to become the next generation of second-line chemotherapy treatment for advanced
  pancreatic cancer. DHA-dFdC overcomes tumor cell resistance to current chemotherapeutic drugs and is well tolerated in preclinical toxicity
  tests. Preclinical studies have also indicated that DHA-dFdC inhibits pancreatic cancer cell growth (up to 100,000-fold more potent that
  gemcitabine, a current standard therapy (for example, the IC50 value of DHA-dFdC is more than 100,000-fold smaller than gemcitabine),
  has documented efficacy against pancreatic tumors in a clinically relevant transgenic mouse model and has demonstrated activities against
  other cancer cell lines, including leukemia, lung and melanoma. Our AML and ALL compounds, developed at the Wake Forest University and
  called KPC34, are next generation targeted therapeutics designed to overcome multiple resistance mechanisms observed with the current
  standard of care. Combined, the Company's drug platform offers a robust drug pipeline focused on the development and commercialization
  of drugs to treat unmet medical needs in oncology. In addition, we are constantly seeking to grow our pipeline to treat unmet medical
  needs in oncology.
  Background*
  Pancreatic cancer is the 3rd
  leading cause of cancer-related death in the United States, surpassing breast cancer. It is expected to become the 2nd leading cause
  of cancer-related death in the United States by the year 2020, surpassing colorectal cancer. In fact, pancreatic cancer has the highest
  mortality rate of all major cancers. Approximately 91% of pancreatic cancer patients will die within five years of diagnosis, only 8%
  will survive more than five years and 74% of patients die within the first year of diagnosis.
  Pancreatic cancer is one of
  the few cancers for which survival has not improved substantially over nearly 40 years. Treatment options for pancreatic cancer include
  surgery, radiation therapy and chemotherapy, which extend survival or relieve symptoms, but seldom produce a cure. Surgical removal of
  the tumor is possible in less than 20% of patients diagnosed with pancreatic cancer because detection is often in late stages and has
  spread beyond the pancreas. The current state of the art chemotherapy treatment is gemcitabine, Folfirinox cocktail or gemcitabine in
  combination with Abraxane.
  *
  Hirshberg Foundation for Pancreatic Cancer Research
  The University of Texas at
  Austin has identified a new drug, DHA-dFdC, that has shown positive results in preclinical studies, inhibiting pancreatic tumor growth
  in clinically relevant transgenic mouse models. In preclinical studies, DHA-dFdC has:
  ●
  inhibited pancreatic cancer cell growth (up to 100,000-fold
  more potent that gemcitabine, a current standard therapy);
  ●
  has documented efficacy against pancreatic tumors in a clinically
  relevant transgenic mouse model;
  ●
  has overcome tumor cell resistance to current chemotherapeutic
  drugs;
  ●
  is well tolerated in preclinical toxicity test;
  ●
  has demonstrated activities against other cancers (e.g. leukemia,
  lung, melanoma); and
  ●
  may stimulate immunogenic cell death to activate host antitumor
  immunity.
  2
  Gem-DHA Technology Summary
  Gem-DHA is a conjugate molecule
  containing gemcitabine linked to a fatty acid called docosahexaenoic acid (DHA). The structure is:
  The DHA structure is illustrated
  above the dashed line in the graphic above and the gemcitabine structure is illustrated below the dashed line. The DHA patent states
  that Gem-DHA was more effective than gemcitabine alone in killing cancer cells in vitro and in vivo in a certain mouse model. The patent
  also states that conjugation of gemcitabine with fatty acids other than DHA did not increase effectiveness over gemcitabine.
  Gem-DHA Published Data
  The science behind Gem-DHA
  has been published in the following peer-reviewed scientific journals:
  ●
  Naguib
  et al
  . (2016) Synthesis, characterization, and
  in vitro and in vivo evaluations of 4-(N)-docosahexaenoyl 2 ́, 2 ́- difluorodeoxycytidine with potent and broad-spectrum antitumor
  activity, NeoPlasia 18: 33-48.
  ●
  Valdes
  et al
  . (2017) Preclinical evaluation of the
  short-term toxicity of 4-(N)-docosahexaenoyl 2 ́, 2 ́- difluorodeoxycytidine (DHA-dFdC), Pharm. Res. 34: 1224-1232.
  ●
  Valdes
  et al
  . (2019) A solid lipid nanoparticle formulation
  of 4-(N)-docosahexaenoyl 2 ́, 2 ́- difluorodeoxycytidine with increased solubility, stability, and antitumor activity, Int.
  J. Pharm. 570:118609
  The portions of the published
  data state the following:
  ●
  The drug unexpectedly concentrates itself in the pancreas
  relative to other organs.
  ●
  It significantly increases the lifespan of mice with pancreatic
  cancer in either mice predisposed to develop the cancer, or into which human pancreatic cancer has been injected.
  ●
  It significantly decreases the growth of pancreatic tumors
  in mice, better than gemcitabine, the current standard of care.
  ●
  An oral formulation using lipid nanoparticles is highly effective
  and stable and has outstanding bioavailability.
  3
  Gem-DHA Patent Coverage
  Gem-DHA has one issued patent
  on the drug itself and one application on the oral formulation, as listed in the following table:
  Number
  Priority
  Expiration
  Title
  App. Serial No. 16/576,127, filed 9/19/2019 as continuation of App. Serial No. 15/115,393, filed 1/29/2015
  1/29/2014
  N/A
  Nucleobase Analogue Derivatives and Their Applications
  U.S. Patent No. 10,463,684, issued 11/5/2019 from App. Serial No. 15/115,393, filed 1/29/2015
  1/29/2014
  10/7/2035
  Nucleobase Analogue Derivatives and Their Applications
  Provisional App. Serial No. 62/858,114, filed 6/6/2019
  6/6/2019
  N/A
  Lipid Nanoparticles Containing Pharmaceutical and/or Nutraceutical agents and methods thereof
  All of this technology has
  been exclusively licensed to the Company for commercial development.
  AML & ALL Cancer
  Our AML and ALL compounds,
  developed at the Wake Forest University and called KPC34, are next generation targeted therapeutics designed to overcome multiple resistance
  mechanisms observed with the current standard of care.
  Background
  Approximately 70% of all AML
  patients are over the age of 60 and only 6.6% of patients are still alive 5 years after diagnosis. Gemcitabine and Cytarabine are the
  backbone of AML and ALL therapy, but life expectancy is poor and relapses are much harder to treat.
  Cytarabine (Ara-C) has been
  a major drug for acute myeloid leukemia (AML) treatment for more than three decades, but KPC34 has shown superior results when tested
  against Cytarabine.
  4
  KPC34 Technology Summary
  KPC34, a conjugate molecule
  made of a gemcitabine molecule linked to a phospholipid, has the following structure:
  Picture in the illustration
  above, to the left of the dashed line is the phospholipid portion and to the right of the dashed line is gemcitabine.
  Gemcitabine is a chemotherapy
  drug used to treat a wide array of cancers, including breast cancer, ovarian cancer, non-small cell lung cancer, pancreatic cancer and
  bladder cancer. The drug interferes with DNA and its function of the phospholipid to which the gemcitabine is linked in KPC34, is to
  inhibit protein kinase C-type enzymes, which are involved in multiple signaling pathways in leukemia.
  The strategy behind targeting
  both DNA synthesis and protein kinase C with one molecule is to double-target different mechanisms of action in leukemia cells and greatly
  reduce the possibility of development of resistance to the drug.
  KPC34 is intended to treat
  the relatively small population of patients with AML and acute ALL. In 2019, an estimated 21,450 people of all ages (11,650 men and boys
  and 9,800 women and girls) in the United States will be diagnosed with AML. AML is the second most common type of leukemia diagnosed
  in adults and children, but most cases occur in adults. AML makes up 32% of all adult leukemia cases (source: https://www.cancer.net/cancer-types/leukemia-acute-myeloid-aml/statistics).
  In 2019, an estimated 5,930 people of all ages (3,280 men and boys and 2,650 women and girls) in the United States were diagnosed with
  ALL (source: https://www.cancer.net/cancer-types/leukemia-acute-lymphocytic-all/statistics).
  The drug is intended for oral
  application, unlike standard chemotherapy drugs, which are given by injection.
  Because of the low patient
  population, and the imminent expiration of the patent, FDA orphan drug status will be sought, which provides expedited review and seven
  years of exclusivity from approval of the new drug application.
  Preliminary data from preclinical
  studies at Wake Forest on the drug includes the following results:
  ●
  kills leukemia cells in vitro;
  ●
  inhibits protein kinase C in biochemical assays;
  ●
  has efficacy against ALL in a mouse model when given orally;
  ●
  has efficacy against central nervous system leukemia in a
  mouse model when given orally;
  ●
  has efficacy against AML exhibiting phosphorylated protein
  kinase C in a mouse model when given orally;
  ●
  based on the mouse models, Wake Forest claims KPC34 exhibited
  efficacy superior to gemcitabine alone or cytarabine (another chemo drug) alone; and
  ●
  KPC34 also appears to overcome resistance to gemcitabine;
  it is effective against gemcitabine-resistant cancer.
  The technology licensed is much broader than KPC34 represents, and
  includes both anticancer and antiviral conjugates, and could include a much broader range of indications, but we have no such drug candidates
  in development other than KPC34.
  5
  KPC34 Patent Coverage
  The KPC34 license includes
  five issued patents, but only one of them covers KPC34. The patent is US7309696, entitled "Compositions and methods for targeting
  cancer cells." It expires on August 11, 2021. All five of the licensed patents will expire by late 2022.
  Licenses
  On April 12, 2018, CBM entered
  into a patent license agreement (the "UT Agreement") with the University of Texas at Austin on behalf of the Board of Regents
  of the University of Texas System. The UT Agreement granted to CBM an exclusive, royalty-bearing license to certain patent applications
  related to nucleobase analogue derivatives and their applications, and specifically to the DHA-dFdC drug candidate. On November 13, 2019,
  the University of Texas at Austin, the Company and CBM entered into an assignment of agreement, whereby CBM assigned all of its rights,
  title and interest to, and obligations under the UT Agreement to the Company.
  On April 17, 2018, CBM entered
  into a license agreement (the "WF Agreement") with Wake Forest University Health Sciences ("WF"). The WF Agreement
  granted to CBM an exclusive, royalty-bearing license to WF's and The University of North Carolina at Chapel Hill's patents
  relating to the KPC34 drug candidate. On November 13, 2019, WF, the Company and CBM entered into an assignment of agreement, whereby
  CBM assigned all of its rights, title and interest to, and obligations under the WF Agreement to the Company.
  On April 13, 2020, the Company
  executed a Master License Agreement (the "UMB License Agreement") with UMB. The UMB License Agreement covers certain antiviral
  compounds discovered by UMB. The compounds seek to inhibit replication of multiple viruses, including Influenza virus, SARS-CoV, MERS-CoV,
  Ebolavirus and Marburg virus. The technology is covered by two patent applications already on file with the United States Patent and
  Trademark Office. The UMB inventors are Drs. Matthew Frieman, Alexander MacKerell and Stuart Watson.
  Commercialization
  Our business success with
  our drug portfolio depends not only on the successful development and approval of the products but also on the commercialization. At
  present, our plan anticipates us making the investments necessary to build an in-house marketing and sales capability for the U.S. market
  for our drug pipeline, or to partner with a larger drug development company to commercialize our drugs as they move through the FDA approval
  process. As our drug compounds make their way through clinical development in the U.S., we intend to approach pharmaceutical and biotechnology
  companies outside the U.S. to negotiate and enter into strategic partnerships that will enable development and commercialization of our
  platform outside the U.S., where we believe the market opportunity is larger than that of the U.S. albeit far more complex to reach.
  We have no operations outside the U.S., nor are we planning to have any non-U.S. operations.
  Manufacturing and Supply
  We do not have any manufacturing
  capabilities and therefore we will have to engage a third party to assist in manufacturing. Such manufacturing will need to be done in
  accordance with good manufacturing practice requirements ("cGMP") regulations, to formulate and manufacture our product candidates.
  A list of third party manufacturers is currently being developed.
  6
  Government Regulation
  Governmental authorities
  in the U.S. and other countries extensively regulate the research, development, testing, manufacture, labeling, promotion, advertising,
  distribution and marketing of pharmaceutical products such as those being developed by us. In the U.S., the FDA regulates such products
  under the FDCA and implements related regulations. Failure to comply with applicable FDA requirements, both before and after approval,
  may subject us to administrative and judicial sanctions, such as a delay in approving or refusal by the FDA to approve pending applications,
  warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions and/or criminal
  prosecution.
  U.S. Food and Drug Administration
  Regulation
  United States Drug
  Development
  In the United States, the
  FDA regulates drugs, medical devices and combinations of drugs and devices, or combination products, under the FDCA and its implementing
  regulations. Drugs are also subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals
  and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of
  substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development
  process, approval process or after approval, may subject an applicant to administrative or judicial sanctions. These sanctions could
  include, among other actions, the FDA's refusal to approve pending applications, withdrawal of an approval, a clinical hold, untitled
  or warning letters, requests for voluntary product recalls or withdrawals from the market, product seizures, total or partial suspension
  of production or distribution injunctions, fines, refusals of government contracts, restitution, disgorgement, or civil or criminal penalties.
  Any agency or judicial enforcement action could have a material adverse effect on us.
  ●
  completion of
                                              extensive pre-clinical laboratory tests, animal studies and formulation studies in accordance
                                              with applicable regulations, including the FDA's Good Laboratory Practice regulations;
  ●
  submission to
                                              the FDA of an IND, which must become effective before human clinical trials may begin;
  ●
  performance of
                                              adequate and well-controlled human clinical trials in accordance with an applicable IND and
                                              other clinical study related regulations, sometimes referred to as good clinical practices,
                                              or GCPs, to establish the safety and efficacy of the proposed drug for its proposed indication;
  ●
  submission to
                                              the FDA of an NDA;
  ●
  satisfactory completion
                                              of an FDA pre-approval inspection of the manufacturing facility or facilities at which the
                                              product, or components thereof, are produced to assess compliance with the FDA's cGMP
                                              requirements;
  ●
  potential FDA
                                              audit of the clinical trial sites that generated the data in support of the NDA; and
  ●
  FDA review and
                                              approval of the NDA prior to any commercial marketing or sale.
  Once a pharmaceutical product
  candidate is identified for development, it enters the pre-clinical testing stage. Pre-clinical tests include laboratory evaluations
  of product chemistry, toxicity, formulation and stability, as well as animal studies. An IND sponsor must submit the results of the pre-clinical
  tests, together with manufacturing information, analytical data and any available clinical data or literature, to the FDA as part of
  the IND. The sponsor must also include a protocol detailing, among other things, the objectives of the initial clinical trial, the parameters
  to be used in monitoring safety and the effectiveness criteria to be evaluated if the initial clinical trial lends itself to an efficacy
  evaluation. Some pre-clinical testing may continue even after the IND is submitted. The IND automatically becomes effective 30 days after
  receipt by the FDA, unless the FDA raises concerns or questions related to a proposed clinical trial and places the trial on a clinical
  hold within that 30-day period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical
  trial can begin. Clinical holds also may be imposed by the FDA at any time before or during clinical trials due to safety concerns or
  non-compliance, and may be imposed on all drug products within a certain class of drugs. The FDA also can impose partial clinical holds,
  for example, prohibiting the initiation of clinical trials of a certain duration or for a certain dose.
  7
  All clinical trials must
  be conducted under the supervision of one or more qualified investigators in accordance with GCP regulations. These regulations include
  the requirement that all research subjects provide informed consent in writing before their participation in any clinical trial. Further,
  an IRB must review and approve the plan for any clinical trial before it commences at any institution, and the IRB must conduct continuing
  review and reapprove the study at least annually. An IRB considers, among other things, whether the risks to individuals participating
  in the clinical trial are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the information regarding
  the clinical trial and the consent form that must be provided to each clinical trial subject or his or her legal representative and must
  monitor the clinical trial until completed.
  Each new clinical protocol
  and any amendments to the protocol must be submitted for FDA review, and to the IRBs for approval. Protocols detail, among other things,
  the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, and the parameters to be used to monitor
  subject safety.
  Human clinical trials are
  typically conducted in three sequential phases that may overlap or be combined:
  ●
  Phase 1. The product
                                              is initially introduced into a small number of healthy human subjects or patients and tested
                                              for safety, dosage tolerance, absorption, metabolism, distribution and excretion and, if
                                              possible, to gain early evidence on effectiveness. In the case of some products for severe
                                              or life-threatening diseases, especially when the product is suspected or known to be unavoidably
                                              toxic, the initial human testing may be conducted in patients.
  ●
  Phase 2. Involves
                                              clinical trials in a limited patient population to identify possible adverse effects and
                                              safety risks, to preliminarily evaluate the efficacy of the product for specific targeted
                                              diseases and to determine dosage tolerance and optimal dosage and schedule.
  ●
  Phase 3. Clinical
                                              trials are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded
                                              patient population at geographically dispersed clinical trial sites. These clinical trials
                                              are intended to establish the overall risk/benefit relationship of the product and provide
                                              an adequate basis for product labeling.
  Post-approval trials, sometimes
  referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These studies are used to gain additional
  experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance
  of Phase 4 trials. Companies that conduct certain clinical trials also are required to register them and post the results of completed
  clinical trials on a government-sponsored database, such as ClinicalTrials.gov in the United States, within certain timeframes. Failure
  to do so can result in fines, adverse publicity and civil and criminal sanctions.
  Progress reports detailing
  the results of the clinical trials, among other information, must be submitted at least annually to the FDA, and written IND safety reports
  must be submitted to the FDA and the investigators for serious and unexpected adverse events, findings from other studies that suggest
  a significant risk to humans exposed to the product, findings from animal or in vitro testing that suggest a significant risk to human
  subjects, and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol
  or investigator brochure. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period,
  if at all. The FDA or the clinical trial sponsor may suspend or terminate a clinical trial at any time on various grounds, including
  a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate
  approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB's requirements
  or if the product has been associated with unexpected serious harm to patients. Additionally, some clinical trials are overseen by an
  independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee.
  This group provides authorization for whether a trial may move forward at designated check points based on access to certain data from
  the study. The clinical trial sponsor may also suspend or terminate a clinical trial based on evolving business objectives and/or competitive
  climate.
  8
  Concurrent with clinical
  trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical
  characteristics of the product and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP
  requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among
  other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final product. Additionally,
  appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does
  not undergo unacceptable deterioration over its shelf life.
  NDA and FDA Review
  Process
  The results of product development,
  pre-clinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the drug,
  proposed labeling and other relevant information, are submitted to the FDA as part of an NDA for a new drug, requesting approval to market
  the product. The submission of an NDA is subject to the payment of a substantial user fee, and the sponsor of an approved NDA is also
  subject to an annual program user fee; although a waiver of such fee may be obtained under certain limited circumstances. For example,
  the agency will waive the application fee for the first human drug application that a small business or its affiliate submits for review.
  The FDA reviews all NDAs
  submitted before it accepts them for filing and may request additional information rather than accepting an NDA for filing. The FDA typically
  makes a decision on accepting an NDA for filing within 60 days of receipt. The decision to accept the NDA for filing means that the FDA
  has made a threshold determination that the application is sufficiently complete to permit a substantive review. Under the goals and
  policies agreed to by the FDA under the Prescription Drug User Fee Act ("PDUFA"), the FDA's goal to complete its substantive
  review of a standard NDA and respond to the applicant is ten months from the receipt of the NDA. The FDA does not always meet its PDUFA
  goal dates, and the review process is often significantly extended by FDA requests for additional information or clarification and may
  go through multiple review cycles.
  After the NDA submission
  is accepted for filing, the FDA reviews the NDA to determine, among other things, whether the proposed product is safe and effective
  for its intended use, and whether the product is being manufactured in accordance with cGMPs to assure and preserve the product's
  identity, strength, quality and purity. The FDA may refer applications for novel drug products or drug products which present difficult
  questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation
  and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations
  of an advisory committee, but it considers such recommendations carefully when making decisions. The FDA will likely re-analyze the clinical
  trial data, which could result in extensive discussions between the FDA and us during the review process. The review and evaluation of
  an NDA by the FDA is extensive and time consuming and may take longer than originally planned to complete, and we may not receive a timely
  approval, if at all.
  Before approving an NDA,
  the FDA will conduct a pre-approval inspection of the manufacturing facilities for the new product to determine whether they comply with
  cGMPs. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with
  cGMP requirements and adequate to assure consistent production of the product within required specifications. In addition, before approving
  an NDA, the FDA may also audit data from clinical trials to ensure compliance with GCP requirements. After the FDA evaluates the application,
  manufacturing process and manufacturing facilities, it may issue an approval letter or a Complete Response Letter. An approval letter
  authorizes commercial marketing of the drug with specific prescribing information for specific indications. A Complete Response Letter
  indicates that the review cycle of the application is complete and the application will not be approved in its present form. A Complete
  Response Letter usually describes all the specific deficiencies in the NDA identified by the FDA. The Complete Response Letter may require
  additional clinical data and/or an additional pivotal Phase 3 clinical trial(s), and/or other significant and time-consuming requirements
  related to clinical trials, nonclinical studies or manufacturing. If a Complete Response Letter is issued, the applicant may either resubmit
  the NDA, addressing all the deficiencies identified in the letter, or withdraw the application. Even if such data and information are
  submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval. Data obtained from clinical trials
  are not always conclusive, and the FDA may interpret data differently than we interpret the same data.
  9
  There is no assurance that
  the FDA will ultimately approve a product for marketing in the United States, and we may encounter significant difficulties or costs
  during the review process. If a product receives marketing approval, the approval may be significantly limited to specific diseases and
  dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA
  may require that certain contraindications, warnings or precautions be included in the product labeling or may condition the approval
  of the NDA on other changes to the proposed labeling, development of adequate controls and specifications, or a commitment to conduct
  post-market testing or clinical trials and surveillance to monitor the effects of approved products. For example, the FDA may require
  Phase 4 clinical trials to further assess drug safety and effectiveness and may require testing and surveillance programs to monitor
  the safety of approved products that have been commercialized. The FDA may also place other conditions on approvals, including the requirement
  for a risk evaluation and mitigation strategy ("REMS"), to assure the safe use of the drug. If the FDA concludes a REMS is
  needed, the sponsor of the NDA must submit a proposed REMS; the FDA will not approve the NDA without an approved REMS, if required. A
  REMS could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution
  methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial
  promotion, distribution, prescription or dispensing of products. Product approvals may be withdrawn for non-compliance with regulatory
  requirements or if problems occur following initial marketing.
  Reimbursement
  Potential sales of any of
  our product candidates, if approved, will depend, at least in part, on the extent to which such products will be covered by third-party
  payors, such as government health care programs, commercial insurance and managed healthcare organizations. These third-party payors
  are increasingly limiting coverage and/or reducing reimbursements for medical products and services. A third-party payor's decision
  to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Further, one payor's
  determination to provide coverage for a drug product does not assure that other payors will also provide coverage for the drug product.
  In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including
  price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment
  measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our future
  revenues and results of operations. Decreases in third-party reimbursement or a decision by a third-party payor to not cover a product
  candidate, if approved, or any future approved products could reduce physician usage of our products, and have a material adverse effect
  on our sales, results of operations and financial condition.
  In the United States, the
  Medicare Part D program provides a voluntary outpatient drug benefit to Medicare beneficiaries for certain products. We do not know whether
  our product candidates, if approved, will be eligible for coverage under Medicare Part D, but individual Medicare Part D plans offer
  coverage subject to various factors such as those described above. Furthermore, private payors often follow Medicare coverage policies
  and payment limitations in setting their own coverage policies.
  Pediatric Exclusivity
  and Pediatric Use
  The Pediatric Research Equity
  Act, or PREA, requires a sponsor to conduct pediatric studies for most drugs and biologics, for a new active ingredient, new indication,
  new dosage form, new dosing regimen or new route of administration. Under PREA, original NDAs, biologics license applications and supplements
  thereto, must contain a pediatric assessment unless the sponsor has received a deferral or waiver. Unless otherwise required by regulation,
  PREA does not apply to any drug for an indication for which an orphan drug designation has been granted. The required assessment must
  assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and support dosing
  and administration for each pediatric subpopulation for which the product is safe and effective. The sponsor or FDA may request a deferral
  of pediatric studies for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding
  that the drug or biologic is ready for approval for use in adults before pediatric studies are complete or that additional safety or
  effectiveness data needs to be collected before the pediatric studies begin.
  10
  Pediatric exclusivity is
  another type of non-patent marketing exclusivity in the United States and, if granted, provides for the attachment of an additional six
  months of marketing protection to the term of any existing regulatory exclusivity, including the non-patent and orphan exclusivity. This
  six-month exclusivity may be granted if an NDA sponsor submits pediatric data that fairly respond to a written request from the FDA for
  such data. The data does not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial
  is deemed to fairly respond to the FDA's request, the additional protection is granted. If reports of requested pediatric studies
  are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity or
  patent protection cover the product are extended by six months.
  Healthcare Laws and
  Regulations
  Sales of our product candidates,
  if approved, or any other future product candidate will be subject to healthcare regulation and enforcement by the federal government
  and the states and foreign governments in which we might conduct our business. The healthcare laws and regulations that may affect our
  ability to operate include the following:
  ●
  The federal Anti-Kickback
                                              Statute makes it illegal for any person or entity to knowingly and willfully, directly or
                                              indirectly, solicit, receive, offer, or pay any remuneration that is in exchange for or to
                                              induce the referral of business, including the purchase, order, lease of any good, facility,
                                              item or service for which payment may be made under a federal healthcare program, such as
                                              Medicare or Medicaid. The term "remuneration" has been broadly interpreted to
                                              include anything of value.
  ●
  Federal false
                                              claims and false statement laws, including the federal civil False Claims Act, prohibits,
                                              among other things, any person or entity from knowingly presenting, or causing to be presented,
                                              for payment to, or approval by, federal programs, including Medicare and Medicaid, claims
                                              for items or services, including drugs, that are false or fraudulent.
  ●
  Health Insurance
                                              Portability and Accountability Act of 1996 ("HIPAA") created additional federal
                                              criminal statutes that prohibit among other actions, knowingly and willfully executing, or
                                              attempting to execute, a scheme to defraud any healthcare benefit program, including private
                                              third-party payors or making any false, fictitious or fraudulent statement in connection
                                              with the delivery of or payment for healthcare benefits, items or services.
  ●
  HIPAA, as amended
                                              by the Health Information Technology for Economic and Clinical Health Act of 2009 and their
                                              implementing regulations, impose obligations on certain types of individuals and entities
                                              regarding the electronic exchange of information in common healthcare transactions, as well
                                              as standards relating to the privacy and security of individually identifiable health information.
  ●
  The federal Physician
                                              Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical
                                              supplies for which payment is available under Medicare, Medicaid or the Children's
                                              Health Insurance Program, with specific exceptions, to report annually to the Centers for
                                              Medicare & Medicaid Services information related to payments or other transfers of value
                                              made to physicians and teaching hospitals, as well as ownership and investment interests
                                              held by physicians and their immediate family members.
  Also, many states have similar
  laws and regulations, such as anti-kickback and false claims laws that may be broader in scope and may apply regardless of payor, in
  addition to items and services reimbursed under Medicaid and other state programs. Additionally, we may be subject to state laws that
  require pharmaceutical companies to comply with the federal government's and/or pharmaceutical industry's voluntary compliance
  guidelines, state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians
  and other healthcare providers or marketing expenditures, as well as state and foreign laws governing the privacy and security of health
  information, many of which differ from each other in significant ways and often are not preempted by HIPAA.
  Additionally, to the extent
  that our product is sold in a foreign country, we may be subject to similar foreign laws.
  Corporate Information
  We were incorporated in
  Delaware on May 1, 1992. Our principal executive offices are located at One Rockefeller Plaza, 11th Floor, New York, New York 10020,
  and our telephone number is (703) 992-9325. Our corporate website address is www.aikidopharma.com. The information contained on or accessible
  through our website is not a part of this prospectus, and the inclusion of our website address in this prospectus is an inactive textual
  reference only.
  11
  The Offering
  Outstanding Common Stock
  As of September 2, 2022, there were 5,485,096  shares of common stock
  issued and outstanding.
  Common Stock Offered
  Up to 294,117 shares of common stock for sale by the selling stockholders for their own account.
  Selling Stockholders
  The selling stockholders are set forth in the Section entitled "Selling Stockholders" of
      this reoffer prospectus on page 15.
  Proceeds
  We will not receive any proceeds from the sale of our common stock by the selling stockholders. We
      would, however, receive proceeds upon the exercise of the stock options by those who receive or received options under the 2014 Plan
      and exercise such options for cash. Any cash proceeds will be used by us for general corporate purposes.
  Risk Factors
  The securities offered hereby involve a high degree of risk. See "Risk Factors."
  Nasdaq
  Symbol
  AIKI
  Unless otherwise indicated, all share numbers in this registration
  statement takes into consideration all reverse stock splits effectuated by the Company since the inception of the 2014 Plan.
  12
  RISK FACTORS
  Investing in our common
  stock involves risk. Before deciding whether to invest in our common stock, you should consider the risks, uncertainties and assumptions
  discussed under the heading
  "
  Risk Factors
  "
  in our Quarterly Reports on Form 10-Q for the fiscal quarters ended
  March 31, 2022 and June 30, 2022 and our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, each as incorporated
  by reference in this reoffer prospectus, any amendment or update thereto reflected in subsequent filings with the SEC, including in our
  annual reports on Form 10-K and quarterly reports on Form 10-Q, and all other information contained or incorporated by reference in this
  reoffer prospectus, as updated by our subsequent filings under the Securities and Exchange Act of 1934, as amended (referred to herein
  as the Exchange Act). There may be other unknown or unpredictable economic, business, competitive, regulatory or other factors that could
  have material adverse effects on our future results. If any of these risks actually occurs, our business, business prospects, financial
  condition or results of operations could be seriously harmed. This could cause the trading price of our common stock to decline, resulting
  in a loss of all or part of your investment. Please also read carefully the section above entitled
  "
  Cautionary Note on Forward-Looking
  Statements.
  "
  13
  USE OF PROCEEDS
  The shares which may
  be sold under this reoffer prospectus will be sold for the respective accounts of each of the selling stockholders listed herein (who
  are our executive officers and directors). Accordingly, we will not realize any proceeds from the sale of the shares of our common stock.
  We will receive proceeds from the exercise of the options; however, no assurance can be given as to when or if any or all of the options
  will be exercised. If any options are exercised, the proceeds derived therefrom will be used for working capital and general corporate
  purposes. All expenses of the registration of the shares will be paid by us. See "Selling Stockholders" and "Plan of
  Distribution."
  14
  SELLING
  STOCKHOLDERS
  This reoffer prospectus
  relates to the shares of our common stock that are being registered for reoffers and resale by selling stockholders who have acquired
  or may acquire shares pursuant to the 2014 Plan. Offers and sales by selling stockholders who are our employees, consultants and "affiliates"
  (as such term is defined in Rule 405 under the Securities Act) are also covered by this reoffer prospectus.
  The selling stockholders are our
  current directors, officers and affiliates who have acquired or may acquire in the future shares of our common stock under the 2014 Plan.
  The selling stockholders may, from time to time, resell all, a portion or none of the shares of our common stock covered by this reoffer
  prospectus. The following table sets forth information as of September 2, 2022 with respect to ownership of our common stock by each
  selling stockholder whose identity is known as of the date of this reoffer prospectus. There is no assurance that any of the selling stockholders
  will sell any or all of the shares offered by them under this Registration Statement. The address for each selling stockholders listed
  below is c/o AIkido Pharma, Inc., One Rockefeller Plaza, 11th Floor, New York, New York 10020.
  Any changed information
  will be set forth in an amendment to the Registration Statement or supplement to this reoffer prospectus, to the extent required by law.
  Inclusion of an individual's name in the table below does not constitute an admission that such individual is an "affiliate"
  of the Company.
  Name
  Number of
  Shares
  Owned (1)
  Number of
  Shares to be
  Offered for
  the Account
  of the Selling
  Stockholder (2)
  Number of
  Shares to
  be Owned
  After
  Offering
  % Owned
  After
  Offering (3)
  Robert J. Vander Zanden (4)
  12,702
  12,688
  12,702
  *
  Anthony Hayes (5)
  84,016
  82,043
  84,016
  1.56
  %
  Tim S. Ledwick (6)
  12,826
  12,688
  12,826
  *
  Paul LeMire (7)
  12,411
  12,411
  12,411
  *
  Robert Dudley (8)
  12,411
  12,411
  12,411
  *
  Gregory Blattner (9)
  12,411
  12,411
  12,411
  *
  Kyle Wool (10 )
  80,058
  80,058
  80,058
  *
  Soo Yu (11)
  8,000
  8,000
  8,000
  *
  Christopher Devall (12)
  8,068
  8,068
  8,068
  *
  Carlos Aldovero (13)
  25,000
  25,000
  25,000
  *
  *
  Less than 1%
  (1)
  Represents common stock owned on or about the date hereof by
  the Selling Stockholders and shares of common stock that are issued or to be issued, or which may be acquired upon the exercise of stock
  options issued or to be issued, or vesting of restricted stock awards issued or to be issued, pursuant to the 2014 Plan as of September 2, 2022.
  (2)
  Represents only shares of common stock that are issued or to
  be issued, or which may be acquired upon the exercise of stock options issued or to be issued, or vesting of restricted stock awards
  issued or to be issued, pursuant to the 2014 Plan. These shares constitute "control securities" as such term is defined
  in General Instruction C to Form S-8.
  (3)
  Percentage is computed with reference to  5,485,096 shares of our Common Stock outstanding as of
                                                                                 September 2, 2022 and assumes for each Selling Stockholder the sale of all shares offered by that particular Selling Stockholder
                                                                                 under the Prospectus.
  (4)
  Dr. Robert J. Vander Zanden is our Chairman of our Board and
  a member of our Board of Directors. The securities to be registered for resale by Mr. Zanden include 9,747 shares of common stock issued
  pursuant to the 2014 Plan and 2,941 shares of common stock issuable upon exercise of outstanding vested options issued pursuant to the
  2014 Plan.
  (5)
  Anthony Hayes is our Chief Executive Officer, Principal Accounting
  Officer, Principal Financial officer, and a member of our Board of Directors. The securities to be registered for resale by Mr. Hayes
  include 79,102 shares of common stock issued pursuant to the 2014 Plan and 2,941 shares of common stock issued upon exercise of outstanding
  vested options issued pursuant to the 2014 Plan.
  (6)
  Tim S. Ledwick a member of our Board of Directors. The securities
  to be registered for resale by Mr. Ledwick include 9,747 shares of common stock issued pursuant to the 2014 Plan and 2,941 shares of
  common stock issuable upon exercise of outstanding vested options issued pursuant to the 2014 Plan.
  (7)
  Gregory James Blattner is a member of our Board of Directors.
  The securities to be registered for resale by Mr. Blattner include 9,470 shares of common stock issued pursuant to the 2014 Plan and
  2,941 shares of common stock issuable upon exercise of outstanding vested options issued pursuant to the 2014 Plan.
  (8)
  Paul LeMire is a member of our Board of Directors. The securities
  to be registered for resale by Mr. LeMire include 9,470 shares of common stock issued pursuant to the 2014 Plan and 2,941 shares of common
  stock issuable upon exercise of outstanding vested options issued pursuant to the 2014 Plan.
  (9)
  Robert Dudley is a member of our Board of Directors. The securities
  to be registered for resale by Mr. Dudley include 9,470 shares of common stock issued pursuant to the 2014 Plan and 2,941 shares of common
  stock issuable upon exercise of outstanding vested options issued pursuant to the 2014 Plan.
  (10)
  Kyle Wool is a member of our Board of Directors. The securities
  to be registered for resale by Mr. Wool include 80,058 shares of common stock issued pursuant to the 2014 Plan.
  (11)
  Soo Yu is a member of our Board of Directors. The securities to be registered for resale by Ms. Yu include 8,000 shares of common stock issued pursuant to the 2014 Plan.
  (12)
  Christopher Devall is our Vice President of Operations. The securities to be registered for resale by Mr. Devall include 8,068 shares of common stock issued pursuant to the 2014 Plan.
  (13)
  Carlos Aldovero is the Chief Executive Officer of one of our subsidiaries. The securities to be registered for resale by Mr. Aldovero include 25,000 shares of common stock issued pursuant to the 2014 Plan.
  15
  PLAN OF DISTRIBUTION
  In this section of the
  reoffer prospectus, the term "selling stockholder" means and includes:
  ●
  the persons identified in the table above as the selling stockholders;
  ●
  those persons whose identities are not known as of the date hereof but may in the future be eligible
      to receive options under the 2014 Plan; and
  ●
  any of the purchasers, assignees, donees, pledgees, distributees, transferees or other successors
      in interest of those persons referenced above who may: (a) receive any of the shares of our common stock offered hereby after the
      date of this reoffer prospectus and (b) offer or sell those shares hereunder.
  The shares of our common
  stock offered by this reoffer prospectus may be sold from time to time directly by the selling stockholders. Alternatively, the selling
  stockholders may from time to time offer such shares through underwriters, brokers, dealers, agents or other intermediaries. The selling
  stockholders as of the date of this reoffer prospectus have advised us that there were no underwriting or distribution arrangements entered
  into with respect to the common stock offered hereby. The distribution of the common stock by the selling stockholders may be effected:
  in one or more transactions that may take place on Nasdaq or any other stock exchange (including one or more block transaction) through
  customary brokerage channels, either through brokers acting as agents for the selling stockholders, or through market makers, dealers
  or underwriters acting as principals who may resell these shares on Nasdaq or any other stock exchange; in privately-negotiated sales;
  by a combination of such methods; or by other means. These transactions may be effected at market prices prevailing at the time of sale,
  at prices related to such prevailing market prices or at other negotiated prices. Usual and customary or specifically negotiated brokerage
  fees or commissions may be paid by the selling stockholders in connection with sales of our common stock.
  The selling stockholders
  may enter into hedging transactions with broker-dealers in connection with distributions of the shares or otherwise. In such transactions,
  broker-dealers may engage in short sales of the shares of our common stock in the course of hedging the positions they assume with the
  selling stockholders. The selling stockholders also may sell shares short and redeliver the shares to close out such short positions.
  The selling stockholders may enter into option or other transactions with broker-dealers which require the delivery to the broker-dealer
  of shares of our common stock. The broker-dealer may then resell or otherwise transfer such shares of common stock pursuant to this reoffer
  prospectus.
  The selling stockholders
  also may lend or pledge shares of our common stock to a broker-dealer. The broker-dealer may sell the shares of common stock so lent,
  or upon a default the broker-dealer may sell the pledged shares of common stock pursuant to this reoffer prospectus. Any securities covered
  by this reoffer prospectus which qualify for sale pursuant to Rule 144 may be sold under Rule 144 rather than pursuant to this reoffer
  prospectus.
  The selling stockholders
  have advised us that they have not entered into any agreements, understandings or arrangements with any underwriters or broker-dealers
  regarding the sale of their securities. There is no underwriter or coordinating broker acting in connection with the proposed sale of
  shares of common stock the selling stockholders.
  Although the shares of
  common stock covered by this reoffer prospectus are not currently being underwritten, the selling stockholders or their underwriters,
  brokers, dealers or other agents or other intermediaries, if any, that may participate with the selling security holders in any offering
  or distribution of common stock may be deemed "underwriters" within the meaning of the Securities Act and any profits realized
  or commissions received by them may be deemed underwriting compensation there under.
  Under applicable rules
  and regulations under the Exchange Act, any person engaged in a distribution of shares of the common stock offered hereby may not simultaneously
  engage in market making activities with respect to the common stock for a period of up to five days preceding such distribution. The
  selling stockholders will be subject to the applicable provisions of the Exchange Act and the rules and regulations promulgated there
  under, including without limitation Regulation M, which provisions may limit the timing of purchases and sales by the selling stockholders.
  In order to comply with
  certain state securities or blue sky laws and regulations, if applicable, the common stock offered hereby will be sold in such jurisdictions
  only through registered or licensed brokers or dealers. In certain states, the common stock may not be sold unless they are registered
  or qualified for sale in such state, or unless an exemption from registration or qualification is available and is obtained.
  We will bear all costs,
  expenses and fees in connection with the registration of the common stock offered hereby. However, the selling stockholders will bear
  any brokerage or underwriting commissions and similar selling expenses, if any, attributable to the sale of the shares of common stock
  offered pursuant to this reoffer prospectus. We have agreed to indemnify certain of the selling security holders against certain liabilities,
  including liabilities under the Securities Act, or to contribute to payments to which any of those security holders may be required to
  make in respect thereof.
  There can be no assurance
  that the selling stockholders will sell any or all of the securities offered by them hereby.
  16
  LEGAL MATTERS
  The validity of the securities
  being offered herein has been passed upon for us by Ellenoff Grossman & Schole LLP, New York, New York.
  EXPERTS
  The consolidated financial
  statements of AIkido Pharma, Inc. as of and for the years ended December 31, 2021 and 2020 incorporated by reference in this Prospectus
  and in the Registration Statement have been so incorporated by reference in reliance on the report of WithumSmith+Brown PC and Marcum,
  LLP, independent registered public accounting firms, incorporated by reference herein, given on the authority of said firm as experts
  in auditing and accounting.
  17
  INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
  We are "incorporating
  by reference" in this reoffer prospectus certain documents we file with the SEC, which means that we can disclose important information
  to you by referring you to those documents. The information in the documents incorporated by reference is considered to be part of this
  reoffer prospectus. Statements contained in documents that we file with the SEC and that are incorporated by reference in this reoffer
  prospectus will automatically update and supersede information contained in this reoffer prospectus, including information in previously
  filed documents or reports that have been incorporated by reference in this reoffer prospectus, to the extent the new information differs
  from or is inconsistent with the old information. We have filed the following documents with the SEC and they are incorporated herein
  by reference as of their respective dates of filing:
  1.
  Our Annual Report on
  Form 10-K
  for the year ended December 31, 2021 as filed with the SEC on March 28, 2022;
  2.
  Our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2022 and June 30, 2022 as filed
      with the SEC on
  May 16, 2022
  and
  August 12, 2022
  , respectively;
  3.
  Our Current Reports on Form 8-K and Form 8-K/A as filed with the SEC on
  January 24, 2022
  ,
  February 11, 2022
  ,
  March 2, 2022
  ,
  March 30, 2022
  ,
  May 25, 2022
  ,
  June 10, 2022
  ,
  June 28, 2022
  ,
  July 6, 2022
  and
  August 19, 2022
  .
  4.
  Our definitive proxy statement
  Schedule 14A
  filed with the SEC on April 12, 2022; and
  5.
  The description of the Company's securities registered under Section 12 of the Exchange Act
      as filed as
  Exhibit 4.1
  on Annual Report on Form 10-K for the year ended December 31, 2021 as filed with the SEC on March 28, 2022.
  All reports and other documents
  (other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits filed in such forms that are related to such
  items unless such Form 8-K expressly provides to the contrary) we subsequently file pursuant to Section 13(a), 13(c), 14 or 15(d) of
  the Exchange Act, prior to the termination of this offering, will also be incorporated by reference in this reoffer prospectus and deemed
  to be part of this reoffer prospectus from the date of the filing of such reports and documents.
  Any statement contained in
  a document incorporated or deemed to be incorporated by reference in this reoffer prospectus shall be deemed modified, superseded or
  replaced for purposes of this reoffer prospectus to the extent that a statement contained in this reoffer prospectus, or in any subsequently
  filed document that also is deemed to be incorporated by reference in this reoffer prospectus, modifies, supersedes or replaces such
  statement. Any statement so modified, superseded or replaced shall not be deemed, except as so modified, superseded or replaced, to constitute
  a part of this reoffer prospectus. None of the information that we disclose under Items 2.02 or 7.01 of any Current Report on Form 8-K
  or any corresponding information, either furnished under Item 9.01 or included as an exhibit therein, that we may from time to time furnish
  to the SEC will be incorporated by reference into, or otherwise included in, this reoffer prospectus, except as otherwise expressly set
  forth in the relevant document. Subject to the foregoing, all information appearing in this reoffer prospectus is qualified in its entirety
  by the information appearing in the documents incorporated by reference.
  You may request, orally or
  in writing, a copy of these documents, which will be provided to you at no cost (other than exhibits, unless such exhibits are specifically
  incorporated by reference), by contacting us at AIkido Pharma, Inc., One Rockefeller Plaza, 11th Floor, New York, New York 10020, Attention:
  Chief Financial Officer, or by telephone at (703) 992-9325. Information about us is also available at our website at www.aikidopharma.com.
  However, the information in our website is not a part of this reoffer prospectus and is not incorporated by reference.
  18
  WHERE YOU CAN FIND MORE INFORMATION
  We have filed a Registration
  Statement with the Securities and Exchange Commission under the Securities Act with respect to the shares of our common stock offered
  by this reoffer prospectus. This reoffer prospectus is part of that Registration Statement and does not contain all the information included
  in the Registration Statement. For further information with respect to our common stock and us, you should refer to the Registration
  Statement, its exhibits and the materials incorporated by reference therein. Portions of the exhibits have been omitted as permitted
  by the rules and regulations of the Securities and Exchange Commission. Statements made in this reoffer prospectus as to the contents
  of any contract, agreement or other document referred to are not necessarily complete. In each instance, we refer you to the copy of
  the contracts or other documents filed as exhibits to the Registration Statement, and these statements are hereby qualified in their
  entirety by reference to the contract or document. The Registration Statement may be inspected and copied at the public reference facilities
  maintained by the Securities and Exchange Commission at Room 1024, Judiciary Plaza, 100 F Street, N.E., Washington, D.C. 20549 and the
  Regional Offices at the Commission located in the Citicorp Center, 500 West Madison Street, Suite 1400, Chicago, Illinois 60661, and
  at 233 Broadway, New York, New York 10279. Copies of those filings can be obtained from the Commission's Public Reference Section,
  Judiciary Plaza, 100 F Fifth Street, N.E., Washington, D.C. 20549 at prescribed rates and may also be obtained from the web site that
  the Securities and Exchange Commission maintains at http://www.sec.gov. You may also call the Commission at 1-800-SEC-0330 for more information.
  We file annual, quarterly and current reports and other information with the Securities and Exchange Commission. You may read and copy
  any reports, statements or other information on file at the Commission's public reference room in Washington, D.C. You can request
  copies of those documents upon payment of a duplicating fee, by writing to the Securities and Exchange Commission.
  DISCLOSURE OF COMMISSION POSITION ON
  INDEMNIFICATION FOR SECURITIES LAW VIOLATIONS
  Section 145 of the Delaware
  General Corporation Law, or Delaware law, inter alia, empowers a Delaware corporation to indemnify any person who was or is a party or
  is threatened to be made a party to any threatened, pending or completed action, suit or proceeding (other than an action by or in the
  right of the corporation) by reason of the fact that such person is or was a director, officer, employee or agent of the corporation,
  or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation or other enterprise,
  against expenses (including attorneys' fees), judgments, fines and amounts paid in settlement actually and reasonably incurred
  by him in connection with such action, suit or proceeding if he acted in good faith and in a manner he reasonably believed to be in or
  not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause
  to believe his conduct was unlawful. Similar indemnity is authorized for such persons against expenses (including attorneys' fees)
  actually and reasonably incurred in connection with the defense or settlement of any such threatened, pending or completed action or
  suit if such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation,
  and provided further that (unless a court of competent jurisdiction otherwise provides) such person shall not have been adjudged liable
  to the corporation. Any such indemnification may be made only as authorized in each specific case upon a determination by the stockholders
  or disinterested directors or by independent legal counsel in a written opinion that indemnification is proper because the indemnitee
  has met the applicable standard of conduct.
  Section 145 further authorizes
  a corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the
  corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation
  or enterprise, against any liability asserted against him and incurred by him in any such capacity, or arising out of his status as such,
  whether or not the corporation would otherwise have the power to indemnify him under Section 145. We maintain policies insuring our officers
  and directors against certain liabilities for actions taken in such capacities, including liabilities under the Securities Act.
  Our amended and restated
  certificate of incorporation, as amended, and amended and restated bylaws require us to indemnify our directors to the fullest extent
  permitted under Delaware law or any other applicable law in effect, but if such statute or law is amended, we may change the standard
  of indemnification only to the extent that such amended statute or law permits us to provide broader indemnification rights to our directors.
  We must indemnify such officers and employees in the same manner and to the same extent that we are required to indemnify our directors
  under our amended and restated certificate of incorporation and amended and restated bylaws. Our amended and restated certificate of
  incorporation limits the personal liability of a director to us or our stockholders to damages for breach of the director's fiduciary
  duty. Pursuant to indemnification agreements we entered into with each of our directors, we are further required to indemnify our directors
  to the fullest extent permitted under Delaware law and our bylaws; provided that each such director shall enjoy the greater of (i) the
  advancement and indemnification rights permitted under our certificate of incorporation and bylaws for directors and officers as of the
  date of such indemnification agreement or (ii) the benefits so afforded by amendments thereto.
  Insofar as indemnification
  for liabilities arising under the Securities Act of 1933, as amended, may be permitted to directors, officers or persons controlling
  us pursuant to the foregoing provisions, or otherwise, we have been advised that in the opinion of the Securities and Exchange Commission,
  such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable.
  19
  You should rely only on the information contained
  in this document. We have not authorized anyone to provide you with information that is different. This document may only be used where
  it is legal to sell these securities. The information in this document may only be accurate on the date of this document.
  Additional risks and uncertainties not presently
  known may also impair our business operations. The risks and uncertainties described in this document and other risks and uncertainties
  which we may face in the future will have a greater impact on those who purchase our common stock. These purchasers will purchase our
  common stock at the market price or at a privately negotiated price and will run the risk of losing their entire investment.
  Up to 294,117 Shares of Common Stock under the AIkido
  Pharma, Inc. 2014 Equity Incentive Plan
  PROSPECTUS
  September 7, 2022
  PART II
  INFORMATION NOT REQUIRED IN PROSPECTUS
  Item
  3. Incorporation of Documents by Reference.
  The Company hereby incorporates by reference into
  this Registration Statement the following documents previously filed with the SEC:
  1.
  Our Annual Report on
  Form 10-K
  for the year ended December 31, 2021 as filed with the SEC on March 28, 2022;
  2.
  Our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2022 and June 30, 2022 as filed
      with the SEC on
  May 16, 2022
  and
  August 12, 2022
  , respectively;
  3.
  Our Current Reports on Form 8-K and Form 8-K/A as filed with the SEC on
  January 24, 2022
  ,
  February 11, 2022
  ,
  March 2, 2022
  ,
  March 30, 2022
  ,
  May 25, 2022
  ,
  June 10, 2022
  ,
  June 28, 2022
  ,
  July 6, 2022
  and
  August 19, 2022
  .
  4.
  Our definitive proxy statement
  Schedule 14A
  filed with the SEC on April 12, 2022; and
  5.
  The description of the Company's securities registered under Section 12 of the Exchange Act
      as filed as
  Exhibit 4.1
  on Annual Report on Form 10-K for the year ended December 31, 2021 as filed with the SEC on March 28, 2022.
  All reports and definitive
  proxy or information statements filed pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act (excluding any information furnished
  pursuant to Item 2.02 or Item 7.01 of any Current Report on Form 8-K) subsequent to the filing of this Registration Statement and prior
  to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which de-registers all
  securities then remaining unsold shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof
  from the date of filing such documents, except as to specific sections of such statements as set forth therein. Any statement contained
  in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes
  of this Registration Statement to the extent that a statement contained in any subsequently filed document which also is deemed to be
  incorporated by reference herein modifies or supersedes such statement.
  Item
  4. Description of Securities.
  Not applicable.
  Item
  5. Interests of Named Experts and Counsel.
  The validity of the shares
  of common stock offered hereby will be passed upon by Ellenoff Grossman & Schole LLP, counsel to the Registrant.
  Item
  6. Indemnification of Officers and Directors.
  Section 145 of the Delaware
  General Corporation Law, or Delaware law, inter alia, empowers a Delaware corporation to indemnify any person who was or is a party or
  is threatened to be made a party to any threatened, pending or completed action, suit or proceeding (other than an action by or in the
  right of the corporation) by reason of the fact that such person is or was a director, officer, employee or agent of the corporation,
  or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation or other enterprise,
  against expenses (including attorneys' fees), judgments, fines and amounts paid in settlement actually and reasonably incurred
  by him in connection with such action, suit or proceeding if he acted in good faith and in a manner he reasonably believed to be in or
  not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause
  to believe his conduct was unlawful. Similar indemnity is authorized for such persons against expenses (including attorneys' fees)
  actually and reasonably incurred in connection with the defense or settlement of any such threatened, pending or completed action or
  suit if such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation,
  and provided further that (unless a court of competent jurisdiction otherwise provides) such person shall not have been adjudged liable
  to the corporation. Any such indemnification may be made only as authorized in each specific case upon a determination by the stockholders
  or disinterested directors or by independent legal counsel in a written opinion that indemnification is proper because the indemnitee
  has met the applicable standard of conduct.
  II-
  1
  Section 145 further authorizes
  a corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the
  corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation
  or enterprise, against any liability asserted against him and incurred by him in any such capacity, or arising out of his status as such,
  whether or not the corporation would otherwise have the power to indemnify him under Section 145. We maintain policies insuring our officers
  and directors against certain liabilities for actions taken in such capacities, including liabilities under the Securities Act.
  Our amended and restated
  certificate of incorporation and amended and restated bylaws require us to indemnify our directors to the fullest extent permitted under
  Delaware law or any other applicable law in effect, but if such statute or law is amended, we may change the standard of indemnification
  only to the extent that such amended statute or law permits us to provide broader indemnification rights to our directors. We must indemnify
  such officers and employees in the same manner and to the same extent that we are required to indemnify our directors under our amended
  and restated certificate of incorporation and amended and restated bylaws. Our amended and restated certificate of incorporation limits
  the personal liability of a director to us or our stockholders to damages for breach of the director's fiduciary duty. Pursuant
  to indemnification agreements we entered into with each of our directors, we are further required to indemnify our directors to the fullest
  extent permitted under Delaware law and our amended and restated bylaws; provided that each such director shall enjoy the greater of
  (i) the advancement and indemnification rights permitted under our amended and restated certificate of incorporation and amended and
  restated bylaws for directors and officers as of the date of such indemnification agreement or (ii) the benefits so afforded by amendments
  thereto.
  Item
  7. Exemption from Registration Claimed.
  All shares of common stock registered
  hereunder for reoffer or resale have been or will be issued to our officers, directors, employees and consultants pursuant to the 2014
  Plan and a restrictive legend is placed on the certificates for the shares of common stock purchased and transfer stops are placed against
  such certificates. Such shares may only be reoffered and sold pursuant to registration under the Securities Act or pursuant to an applicable
  exemption under the Securities Act. As a result, such offers and sales are exempt from the registration requirements of the Securities
  Act pursuant to the provisions of Section 4(a)(2) of the Securities Act.
  Item
  8. Exhibits.
  Number
  Description
  4.1
  AIkido Pharma, Inc. 2014 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 of the Registrant's Registration Statement on Form S-8 filed on July 15, 2014)
  5.1
  Opinion of Ellenoff Grossman & Schole LLP (*)
  5.2
  Opinion of Nixon Peabody LLP (incorporated by reference to Exhibit 5.1 of the Registrant's Registration Statement on Form S-8 filed on July 15, 2014)
  23.1
  Consent of Ellenoff Grossman & Schole LLP (included in Exhibit 5.1)
  23.2
  Consent of WithumSmith+Brown, PC (*)
  23.3
  Consent of Marcum LLP (*)
  24.1
  Power of Attorney (included in the signature page to this Registration Statement)
  107.1
  Filing Fee Table (*)
  *
  Filed herewith
  II-
  2
  Item
  9. Undertakings.
  (a)
  The Registrant hereby undertakes:
  (1) To
  file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
  (i) To
  include any prospectus required by Section 10(a)(3) of the Securities Act;
  (ii) To
  reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective
  amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration
  Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities
  offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range
  may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in
  volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the "Calculation
  of Registration Fee" table in the effective Registration Statement;
  (iii) To
  include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any
  material change to such information in the Registration Statement;
  Provided, however
  , that
  paragraphs (a)(1)(a) and (a)(1)(b) do not apply if the Registration Statement is on Form S-8 and the information required
  to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the SEC
  by the Registrant pursuant to Section 13 or 15(d) of the Exchange Act that are incorporated by reference in the Registration
  Statement.
  (2) That,
  for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new
  Registration Statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to
  be the initial
  bona fide
  offering thereof.
  (3) To
  remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination
  of the offering.
  (b) The
  Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant's
  annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee
  benefit plan's annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the
  Registration Statement shall be deemed to be a new Registration Statement relating to the securities offered therein, and the offering
  of such securities at that time shall be deemed to be the initial
  bona fide
  offering thereof.
  (c) Insofar
  as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of
  the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such
  indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim
  for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer
  or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer
  or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the
  matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification
  by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
  II-
  3
  SIGNATURES
  Pursuant to the requirements of
  the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for
  filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized,
  in the City of New York, State of New York, on September 7, 2022.
  AIKIDO PHARMA, INC.
  /s/ Anthony Hayes
  Name:
  Anthony Hayes
  Title:
  Chief Executive Officer
  (Principal Executive Officer,
  Principal Financial Officer and
  Principal Accounting Officer)
  POWER OF ATTORNEY
  KNOW ALL PERSONS BY THESE
  PRESENTS
  , that each person whose signature appears below does hereby constitute and appoint Michael Rice with full power of substitution,
  such person's true and lawful attorneys-in-fact and agents for such person, with full power and authority to do any and all acts
  and things and to execute any and all instruments which said attorneys and agents, and any one of them, determine may be necessary or
  advisable or required to enable said corporation to comply with the Securities Act of 1933, as amended, and any rules or regulations
  or requirements of the Securities and Exchange Commission in connection with this Registration Statement. Without limiting the generality
  of the foregoing power and authority, the powers granted include the power and authority to sign the names of the undersigned officers
  and directors in the capacities indicated below to this Registration Statement, to any and all amendments, both pre-effective and post-effective,
  and supplements to this Registration Statement, and to any and all instruments or documents filed as part of or in conjunction with this
  Registration Statement or amendments or supplements thereof, and each of the undersigned hereby ratifies and confirms that all said attorneys
  and agents, or any one of them, shall do or cause to be done by virtue hereof. This Power of Attorney may be signed in several counterparts.
  Pursuant to the requirements
  of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons on behalf of the Registrant
  in the capacities and on the dates indicated.
  Signature
  Title
  Date
  /s/ Anthony Hayes
  Chief Executive Officer
  September 7, 2022
  Anthony Hayes
  (Principal Executive Officer,
  Principal Accounting Officer,
  Principal Financial Officer and Director)
  /s/ Robert J. Vander Zanden
  Director and Chairman of the Board of
  September 7, 2022
  Robert J. Vander Zanden
  Directors
  /s/ Tim S. Ledwick
  Director
  September 7, 2022
  Tim S. Ledwick
  /s/ Paul LeMire
  Director
  September 7, 2022
  Paul LeMire
  /s/ Robert Dudley
  Director
  September 7, 2022
  Robert Dudley
  /s/ Gregory Blattner
  Director
  September 7, 2022
  Gregory Blattner
  /s/ Kyle Wool
  Director
  September 7, 2022
  Kyle Wool
  /s/ Soo Yu
  Director
  September 7, 2022
  Soo Yu
  II-4